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Abstract
“I was not sick and I didn’t need to recover”: Methadone Maintenance Treatment as a refuge
from criminalization

By
David Frank
Advisor: Barbara KatzRothman
Methadone Maintenance Treatment (MMT) has been undergoing a cultural and epistemological
shift away from an approach that emphasized client stabilization and a reduction of social harms
towards one grounded in values associated with the recovery movement. These changes include
promoting a view of addiction grounded in the disease model as well as efforts to make
abstinence and ancillary services such as recovery coaching/counseling, programs emphasizing
proper citizenship, and concern for clients’ spirituality necessary parts of the program. As such,
the increasing use of recovery as the dominant conceptual framework for MMT represents a
change in how methadone, MMT, and those who use it are socially constructed. Recovery,
which is based on theories of addiction-as-disease, is seen by some as a means to restore MMT
to its rightful position as a medically-based treatment for addiction and a way to remove stigma
from individuals on the program. Others believe that the shift will act as a form of social control
by pathologizing drug use/users and obscuring the role of structural forces (criminalization) in
the harms experienced by drug users. Moreover, by constructing PWUD’s choice to attend MMT
as unrelated to the ways that they are oppressed under criminalization, the recovery discourse
depoliticizes drug treatment issues, and, as such, implicitly supports the status quo
criminalization of PWUD. This dissertation uses qualitative interviews and ethnographic
methods to examine: how the shift towards recovery affects issues of agency and control among
iv

individuals on MMT; how it influences debates over methadone’s role as a form of drug
treatment; and how addiction more generally is being constructed by the recovery discourse.
Results demonstrate that despite MMT’s institutional focus on recovery, most participants linked
their use of MMT to the structural-legal context of prohibition/criminalization rather than
through the narrative of the recovery model. Responses also suggested the recovery model
functions in part to obscure the role of criminalization in the harms PWUD experience in favor
of a model based on individual pathology. Thus, in contrast to the recovery model, MMT cannot
be understood outside of the structural context of criminalization and the War on Drugs which
shape illegal drug use as a difficult and dangerous activity, and consequently position MMT as a
way to moderate or escape from those harms.
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Chapter 1 - Introduction

For the last 10-15 years, Methadone Maintenance Treatment (MMT) in the United States
has been undergoing a cultural and epistemological shift away from an approach that emphasized
client stabilization and a reduction of social harms towards one grounded in values associated
with the recovery movement (Laszlo_editor, 2016; Substance Abuse and Mental Health Services
Association [SAMHSA], 2015; White & Mojer-Torres, 2010). These changes include promoting
a view of addiction grounded in the disease model as well as efforts to make abstinence from all
substances (as opposed to just illegal opioids) as necessary parts of the program (Recovery
Oriented Methadone Maintenance [ROMM] Client Placement in Phases of Treatment, 2011;
White & Mojer-Torres, 2010). Moreover, since recovery conceptualizes addiction as a wholeperson malady, it also involves a focus on ancillary services such as recovery
coaching/counseling, programs emphasizing proper citizenship, and concern for clients’
spirituality (White, 2007; White & Mojer-Torres, 2010).
As such, the increasing use of recovery as the dominant conceptual framework for MMT
represents a change in how methadone, MMT, and those who use it are socially constructed.
Whereas previous descriptions of MMT incorporated a focus on its pragmatic benefits including reduced rates of prisoner recidivism, overdose, and rates of blood-borne disease
transmission (Drucker et al., 1998; Joseph, Stancliff & Langrod, 2000; Bigg, 2001) - as
legitimate motivations for engaging with treatment, MMT under recovery is more focused on
ideology. Individuals, described as “patients”, are increasingly expected conform to a medical
narrative of treatment that includes a focus on the innate wrongness of drug use, the necessity of
personal change, and a conception of addiction grounded in the disease model (White & MojerTorres, 2010; White, 2012). Therefore, the construction of MMT as a vehicle towards recovery
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may devalue its more strategic functions which can be practical rather than value-based and are
often linked to a structural critique of policies that criminalize drug users.
Although recovery is seen by some as a means to restore MMT to its rightful position as
a medically-based treatment for addiction and a way to remove stigma from individuals on the
program, it may not represent the experiences, or meet the needs, of a diverse population of
people who use drugs who have very different drug use experiences, and who conceptualize their
drug use and treatment goals differently. First, many people on MMT are using the program
strictly as a means to reduce or eliminate their illegal opioid use and see MMT as unrelated to
other forms of substance use. Others are not interested in abstinence as a treatment goal (or as
defined by the recovery model) but use the program instead as a means of reducing harms related
to active drug use such as overdose, withdrawal, and the constant hustle of dependence on illegal
opioids. Such individuals, who benefit from MMT but are not seeking (or have not yet achieved)
complete abstinence from all substances potentially face increased marginalization and discipline
at their clinic, up to and including dismissal from the program – an outcome associated with
increased risk of overdose, transmission of blood-borne diseases, and death (Magura &
Rosenblum, 2001). Thus, the increasing use of recovery-based policies in MMT may hinder its
ability to act as a form of harm reduction in the lives of drug users, thereby exposing them to the
comparatively greater dangers of illegal drug use. This is particularly important in the current
U.S. context of dramatic increases in opioid-involved overdoses (CDC, 2016).
Moreover, positioning MMT as being ‘about recovery’ has significant implications for
the ways that drug use, drug treatment, and drug control are understood. The recovery model
locates the difficulties illegal drug users encounter and their reasons for pursuing MMT as
individually based, through addiction, rather than from structural forms of oppressions such as
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criminalization and the War on Drugs. As such, the contextual reality of criminalization as a
force of harm in illegal drug users’ lives, and one that drives them towards the relatively safer
form of opioid use available within MMT is obscured from the narrative. Using the same logic,
positive treatment outcomes in MMT are seen as the result of a medical intervention rather than
because of the quasi-legal environment of opioid use that MMT facilitates. Thus, the recovery
model implicitly supports criminalization by locating drug users as the architects of their own
problems while absolving state policies that criminalize them from responsibility.
This dissertation critically examines recovery in MMT, focusing both on how well its
tenets and claims align with the goals and experiences of people in the program, as well as how
the narrative of recovery affects related discourses of drug use and treatment.
Background
Recovery has been gaining considerable traction within substance use treatment,
including MMT for the last 15 years (Humphreys & Lembke, 2014; Laudet, 2007; White &
Mojer-Torres, 2010). It has been embraced by leading government agencies in the United States
(U.S.) like the Substance Use and Mental Health Service Administration (SAMHSA) (2015) and
the Office of National Drug Control Policy (ONDCP) (2012), as well as non-government groups
like Medication Assisted Recovery Services (MARS) (2016) and Faces and Voices of Recovery
(Faces and Voices of Recovery, 2016; Laszlo_editor, 2016) who advocate for greater
incorporation of recovery-based principles into MMT and other substance use treatment
modalities.
Recovery’s meaning

3

While the term ‘recovery’ has always been understood to mean the cessation of a
particular illness or ailment, the modern recovery discourse has its roots in the 19th century when
temperance societies and related groups began discussing socially unacceptable alcohol use as a
disease (Levine, 1978). The concept and language of recovery was later taken up by twelve-step
groups who formed around a variety of practices including drinking, smoking, and narcotics use
(White, Kelly & Roth, 2012). Although the move towards policies aimed at recovery has been
occurring internationally, efforts in the United Kingdom (UK), Australia, and the U.S. have
attracted the most attention (AIVL, 2012; UK Home Office, 2012). One important difference
between the U.S.-based approach and those of the UK and Australia has been their stance on
MMT; while recovery-based polices in the UK and Australia have focused on reducing use of
MMT, seen as allowing individuals to “drift ….into indefinite maintenance, which is a
replacement of one dependency with another” (UK Home Office, 2012: p. 3), U.S. agencies have
adopted a view of recovery that sees MMT as on par with other legally-prescribed medications
and thus, as an acceptable medical treatment for addiction (SAMHSA, 2009). Nevertheless, the
US-based approach to recovery for those on MMT, often termed “Recovery Oriented Methadone
Maintenance” (ROMM) maintains the same focus on abstinence, citizenship, and “improvement
in global health”, with the caveat that individuals taking their methadone as prescribed and
otherwise meeting criterion for recovery are included within the definition (White & MojerTorres, 2010).
Although the specific criteria comprising recovery varies and is to some extent contested
(White, 2012; Neale, Nettleton & Pickering, 2011), in the U.S., most definitions are based on
that of the Betty Ford Institute Consensus Panel which defined recovery as “a voluntarily
maintained lifestyle characterized by sobriety, personal health and citizenship” (2007: p. 222).
4

SAMHSA uses a similar definition centered on four “major dimensions” including health, home,
purpose, and community (2016). Thus while abstinence is considered a prerequisite 1, recovery is
based on a holistic conception of personhood that is understood as a lifelong process of growth,
change, and reclamation of the self (Laudet, 2007; White, 2007). Recovery advocates William
White and Lisa Mojer-Torres contrast recovery with remission, meaning abstinence in this
context, stating: “Remission is about the subtraction of pathology; recovery is ultimately about
the achievement of global (physical, emotional, relational, spiritual) health, social functioning,
and quality of life in the community” (2010: p. 8). Thus, recovery involves a full-fledged change
in personhood in accordance with normative ideas about “how bodies should function and about
desirable as opposed to undesirable ways of being” (Keane, 2002: p. 16) rather than simply
abandoning ‘problematic’ drug use. This whole-person focus also greatly expands the
jurisdictional boundaries of methadone clinics to intervene in multiple aspects of their clients’
lives.
Recovery and disease
The notion of addiction-as-disease is central to recovery in that it establishes the
condition one must recover from. Although there is flexibility regarding how the disease is
operationalized (usually ranging from views based on the National Institute of Drug Abuse
(NIDA)’s chronic brain disease model (Courtwright, 2010) to more mainstream conceptions
associated with 12-step groups), recovery rests on the claim that “addiction” is a diagnostic,
pathological condition requiring treatment, in this case methadone alongside a battery of psycho-

1

It is beyond the scope of this paper to discuss the definitional and taxonomic problems associated with culturally
determined and highly unstable categories like “drug” or “abstinence” (see for example Keane, 2002), however, it
should be noted that these same difficulties problematize their use in recovery settings too.
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social-spiritual interventions. Yet, despite its current dominance culturally, addiction-as-disease
theories are far from universally accepted. Scholars from numerous disciplines point out that
they are both scientifically flawed and serve as a means of social control (Lewis, 2015; Conrad
& Schneider, 1992; Vrecko, 2010; Peele, 2014; Hart, 2013; Keane, 2002; Reinarman, 2005; Des
Jarlais, 1995). Addiction-as-disease theories have also been described as stigmatizing, and as
providing support for repressive drug policies, particularly towards poor and marginalized
peoples, through their focus on people who use drugs as pathological (Campbell, 2012; Levy,
2014; Reinarman, 2005). Examining methadone as one of many “technologies of addiction
therapeutics”, science and technology scholar Nancy Campbell argues that medical and criminal
theories of drug use support and co-produce one another as well as “the very forms of addicted
subjectivity to which they are said to respond.” (Campbell, 2011: p. 124).
Moreover, evidence demonstrates that people use, and benefit from MMT outside of the
context of the disease/recovery model (Bigg, 2001; Joseph, Stancliff & Langrod, 2000; Drucker
et al., 1998). Harm reductionists point out that people often utilize MMT for pragmatic reasons
including withdrawal avoidance, which in turn reduces the likelihood of risky activity such as
syringe sharing; as a temporary means of reducing tolerance and physical wear-and-tear; and as a
means for dealing with instabilities of the illegal drug market (Harris & Rhodes, 2013; MateuGelabert et al., 2010; Koester, Anderson & Hoffer, 1999). MMT has also consistently been
shown to reduce overdose, recidivism, and transmission of blood-borne viruses (Novick et al.
2015; Joseph, Stancliff & Langrod, 2000)
A review of the early literature suggests that physicians Dole and Nyswander – who did
the foundational research leading to MMT in the mid-1960s – valued its potential to reduce
structural-legal harm in drug users’ lives. They argue that “Methadone maintenance makes
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possible a first step toward social rehabilitation by stabilizing the pharmacological condition of
addicts (sic) who have been living as criminals on the fringe of society” (Dole & Nyswander,
1976: p. 2117). Moreover, in their ten-year review of MMT, they argue against excessive rules
and regulations which they cite as the most common reason for “addicts” to reject treatment, and
chastise the public at large for their morally-based lack of enthusiasm for substitution treatment,
pointing out that “What was not anticipated at the onset was the nearly universal reaction against
the concept of substituting one drug for another, even when the second drug enabled the addict
(sic) to function normally.” (p. 2117)
Resistance to recovery
There has also been resistance to the growing dominance of recovery, both in general,
and as it relates to MMT (Australian Injecting and Illicit Drug Users League [AIVL], 2012;
International Network of People who Use Drugs [INPUD], 2015; INPUD, 2014). Organizations
that support the rights of people who use drugs including the International Network of People
who use Drugs (INPUD) and the Australian Injecting & Illicit Drug Users League (AIVL) do not
oppose the rights of individuals to identify as “in recovery”, or pursue recovery-based goals, but
argue against the elevation of such personal choices to the level of policy where it becomes a
standard that is forced upon everyone (AIVL, 2012; INPUD, 2014). Such groups argue that
rather than a disease, drug use is a “social phenomenon that is characterized by a high level of
diversity, not ‘sameness’ (AIVL, 2012: p. 3). According to this view, recovery functions as a
meta-narrative that necessarily implies “that drug use is a disease from which people could or
should be cured” (INPUD, 2014, para. 7).
Yet, with important exceptions (Harris & Rhodes, 2013; Fisher et al., 2002; Koester et
al., 1999) the majority of scholarship on MMT does not account for how criminalization and the
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War on Drugs shape the treatment experiences of people on the program. Similarly, there has
been a lack of critical engagement with the increasing emphasis on conceptualizing MMT as
recovery-based treatment (in the U.S. 2). By examining alternative constructions that
acknowledge its use as a pragmatic strategy to mitigate harms produced structurally by
criminalization, this dissertation hopes to produce a richer, more contextualized picture of MMT
and the reasons people who use drugs employ its services. Moreover, a more nuanced
understanding of why people use/value/benefit from MMT may open up discursive spaces to
examine the etiology of harms they experience as a product of oppression rather than solely from
the pharmacological and physiological effects of substances.
Literature Review
This dissertation is based upon the following literature domains:
Medicalization
From the 1970’s through recently, Health and Illness scholars documented the
medicalization of deviance, a process whereby behaviors not necessarily conceptualized
medically are increasingly seen as illnesses (Conrad and Schneider, 1992; Zola, 1972; Szasz,
1974). Cultural trends including the emergence and increasing professionalization of medicine,
the reduced role of religion, the emergence of biophysiological theories of causation and the
increasing social desirability of “treating” rather than punishing, all contribute to the shifting
designation of deviance, from one of badness to one of sickness (1992). Moreover, because of
cultural perceptions that link medicine and science generally with notions of objectivity,

2

There has been more critique of recovery-based policies in the UK and Australian contexts. For example, see
Australian Injecting and Illicit Drug Users League (AIVL, 2012).
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behaviors are defined (and accepted) as either normal or pathological based on the views of the
medical profession (Keane, 2002; Vrecko, 2010).
One hallmark of medicalization has been its ability to exert social control through “the
authority to define certain behaviors, persons, and things.” (Conrad, 1992: p. 216). As such
medicalization is always about power, and which groups are able to establish and legitimate their
definitions of morality and deviance (Conrad, 1992; Jutel, 2010). Scholars examining
medicalization (see for example Zola, 1972, Illich, 1975, Rosencrance, 1985, Wilkerson, 1998)
note that it derives much of its power through its ability to “construct and promote deviance
categories with wide-ranging application” (1992: 23). For example, In From Badness to
Sickness, a foundational text in the medicalization literature, Conrad and Schneider take as their
starting point the idea that what is deviant in a particular society is not self-evident and term the
social-political battle for meaning the “politics of definition” (1992). Hence, the ability to define
(and to legitimate definitions of) certain behaviors, activities, or conditions as deviant is a
political activity that is enmeshed within, and dependent upon power relations. This view, which
builds upon both Marxist and Constructionist understandings of deviance (see for example
Quinney, 1974; Foucault, 1973; Gusfield, 1963) sees the creation of deviance categories as an
ideological contest involving a variety of class, status, and/or group interests, with respective
actors all working to promote particular definitions that align with their goals. Thus, the notion
of a Politics of Definition is helpful towards analyzing a complex cultural environment, like that
of MMT, which does not easily conform to narratives of Medicalization and De-medicalization.
Although MMT has often been viewed as an example of the medicalization of deviance
(Conrad & Schneider, 1992; Stevens, 2000), it is also a site of contestation and resistance, seen
by some as a strategic means of survival in a regime that criminalizes people who use (certain)
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drugs (Harris & Rhodes, 2013; Mateu-Gelabert et al., 2010; AIVL, 2012). Thus, the increasing
use of recovery as the dominant conceptual framework for MMT represents an attempt to
medicalize a program that is currently informed by multiple, and often conflicting points of view.
Scholars have also pointed out how medical categories like “healthy” are innately
normative – thus they reflect the inequalities within our hierarchical society (Vogt, Hofmann, &
Getz, 2016; Clark, 2014) For example, Susan Fraser points out that treatment responses both
emerge from, and help construct regulatory norms based on “what it means to be human, citizen,
woman or man.” (Fraser & Valentine, 2008: p. 2). As such, treatment becomes a particularly
effective means of disciplining and controlling subjectivities (see for example, Fraser &
Valentine, 2008; Bougois, 2000; Foucault, 1973; Keane, 2002; Carr, 2011; Szasz, 1974).
Calls to define MMT through medical narratives have typically been framed by
proponents as an effort to remove negative stigma associated with methadone and to grant
individuals in MMT the more socially acceptable role of “patients” recovering from the disease
of addiction (White & Mojer-Torres, 2010; White, 2012). Yet, those opposed to the recovery
definition, such as drug-user rights groups, point out that such labeling restricts many to an
unwanted disease category and obscures the role of structural-legal determinants in the harms
experienced by drug users, thereby implicitly supporting anti-drug policies that criminalize them
(INPUD, 2014; AIVL, 2012). Hence, the label of recovery and its relationship to theories of
addiction-as-disease becomes a site of ideological contestation between groups with different
beliefs, goals, and frames of reference for understanding the issue.
Proponents of disease theories of behavior argue that by designating a behavior’s etiology
as biophysical rather than moral, stigmatization and social marginalization will be reduced, or
potentially eliminated (Berghmans et al., 2009; Rosenbaum, 1995). However, this has been
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challenged by health and illness scholars who point out that modern, neo-liberal conceptions of
health are intimately linked to notions of morality and that the unhealthy individual is
increasingly seen as responsible for her plight by not making the (morally) correct (healthy)
choices (Hansen, Bourgois & Drucker, 2014; Payton & Thoits, 2011; Lupton, 1995; Petersen,
1997). Moreover, a central critique of medicalization focuses on its ability to decontextualize
individuals and their behaviors from the social world, thereby ignoring the role of social
structures and/or institutions that give rise and contextual meaning to medical diagnoses
(Conrad, 1992, Crawford, 1980). Building on Foucault, Robert Crawford points out how
medicalization restricts notions of causality to the individual body and that “anything which
cannot be shown to interact with the organism to produce a morbid state is increasingly
excluded” (Crawford, 1980: 371). Scholars have noted how the adoption of a biomedical model
of senile dementia neglects the role of social factors (Lyman, 1989), and how medicalized
conceptions wife battering focus primarily on therapy at the expense of a critical analysis of
patriarchy (Tierney, 1982). Drug-user rights groups have expressed similar claims in regards to
the medicalization of addiction (AIVL, 2012; INPUD, 2011).
More recent work on medicalization has focused on the increasingly complex, multidirectional and technoscientifc processes of medicalization, termed biomedicalization (Campbell,
2012; Clarke et al., 2003). Biomedicalization extends the medicalization project through its
increasing focus on health as a moral obligation, and attendant growth of surveillance and risk
assessment aimed at individual bodies (2003). Moreover, biomedicalization points to the ability
of emerging technological forms of intervention and surveillance as a highly effective means of
producing and monitoring individual subjectivities (2003).
Addiction as disease:
11

Humans have used psychoactive substances for many thousands of years for a variety of
reasons including religious activities, ritual, relaxation, and amusement (Weil, 1972). Yet,
notions of addiction, conceived by the new paradigm as “a disease, or disease-like” began to
form in the late 18th and early 19th century around the concept of alcoholism (Levine, 1978: 493).
Central to the developing model of alcoholism-as-disease is the role of the will in choices to use
or abstain from alcohol (1978). During the 17th century, individuals were seen to drink and/or
get drunk because they wanted to, rather than because they had to. Yet, towards the end of the
18th century, individuals began describing their relationship to alcohol as one of overwhelming
compulsion (Levine, 1978). This occurred in tandem with newly formed temperance
organizations that developed theories about addiction centered on the notion of a disabled will,
and abstinence as its only cure. Levine argues that this view of alcoholism was subsequently
applied to other substances, and forms the basis of current understandings of addiction (1978).
While modern conceptions of addiction-as-disease continue to focus heavily on the
notion of a disabled will and abstinence as its proscribed treatment, they are now seen primarily
through a neurological lens that describes addiction as a “chronic brain disease” (Leshner, 1997;
Volkow & Fowler, 2000). This is the view advanced by the American National Institute on Drug
Abuse (NIDA), which funds most of the world’s research on addiction and therefore exercises
considerable influence over how it is framed (NIDA, 2007). Moreover, the neurological model
draws much of its power from its relationship to science, seen as objective and free of influence
by external, social factors (Vrecko, 2010; Buchman, Skinner & Illes, 2010).
Yet, the neurological model of addiction-as-disease also has many critics. Scholars have
been critical of the science supporting the disease model by arguing that neurobiological
accounts of addiction are reductive and ignore the role of social and cultural factors (Peele 1999;
12

Keane, 2002; Buchman, Skinner & Illes, 2010). Others have pointed out that rather than
liberating drug users from stigma and social exclusion, disease models of addiction retain their
moral character and often function as a force of disempowerment and marginalization (Granfield
& Cloud 1999; Peele, 2014). Similarly, in Addiction as Accomplishment, sociologist Craig
Rienarman rejects the notion that addiction-as-disease theories emerged objectively from
science, writing: “The disease concept was invented under historically and culturally specific
conditions, promulgated by particular actors and institutions, and internalized and reproduced by
means of certain discursive practices” (2005: p. 308).
Recovery
Much of the scholarship on the emergence of recovery in drug treatment modalities
(particularly in the U.S.) is based on an un-critical acceptance of recovery, both as a positive
treatment outcome and as the proper organizational structure for MMT programs. Most articles
focus either on the best ways to encourage illegal drug users - understood as “addicts” - to pursue
recovery-based treatment or how to best organize programs according to recovery-based
treatment principles (White & Mojer-Torres, 2010; Vanderplasschen et al., 2013). This may be
due in part to the stigma of MMT as compared to non-medication using treatment like 12-step
models (Frank, 2011). People on MMT have typically been excluded from claims to recovery
due to the belief that they were not truly abstinent. Thus, much of the scholarship related to
MMT and recovery involves claims to MMT’s legitimacy in regards to recovery-status (as well
as articles on how best to integrate the two approaches) rather than critical examinations of
recovery as a concept and/or treatment model (White, 2010; White, 2009). Others focus on ways
to bridge gaps between abstinence/recovery-based and harm reduction-based treatment
approaches (Futterman, Lorente & Silverman, 2004; Kellogg, 2003).
13

The most clearly articulated model of recovery-based treatment in MMT, termed
Recovery Oriented Methadone Maintenance (ROMM) is authored by well-known recovery
advocates William White and Lisa Mojer-Torres (2010). ROMM is firmly based in a conception
of “Opioid Addiction as a Chronic Disease” (2010: 3) and views drug users as “patients” in need
of both medical treatment and a variety of self-help/social-psychological services (2010).
ROMM calls for a number of recovery-focused interventions including the use of paid or
volunteer recovery coaches; inclusion of indigenous healers and healing practices within Opioid
Treatment Programs (OTPs); celebrating patient recovery milestones; and “visibly participating
(OTP staff and MM patients/families) in local recovery celebration events” (p. 15).
Moreover, ROMM links the acceptance of its principles to the ability of individuals to
access “take-homes”, daily/weekly/monthly doses of methadone given to individuals in order to
avoid their being forced to attend the clinic every day (ROM Phases of Treatment, 2011). For
example, according to the ROMM guidelines, in order to receive any take-home doses,
individuals must: establish direct relationships with organizations that may lend support to
recovery; be engaged in recovery support activities; demonstrate awareness of how alcohol and
other drug use negatively effects recovery; and be exploring spirituality (ROM Phases of
Treatment, 2011: 6). Thus, ROMM explicitly links the ability of individuals to access treatment
to their acceptance of recovery-based principles and practices.
Harm Reduction
Harm Reduction is an approach to drug use (and other activities) that seeks to reduce
associated harms by providing services outside of the abstinence-only context that defines most
traditional forms of drug treatment (HRC, 2014). Typical examples include Syringe-Exchange
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Programs (SEPs), Safer Injection Facilities (SIFs), and providing drug users with naloxone, an
opiate antagonist that reverses the effects of opioid-based overdoses.
Although it’s difficult to establish a definitive historical beginning for the harm reduction
movement and any account of its inception will leave out important precursors, it is thought to
have begun in England and Amsterdam during the early 1980’s as both areas were dealing with
rapidly increasing rates of drug use (particularly heroin) and related harms such as overdose,
Hepatitis C, and the first signs of the HIV/AIDS epidemic (Stoker, 2006-2010; Riley et al. 2012).
The early proponents of harm reduction began to coalesce around a common frustration with
existing drug policies whose primary goals were to eliminate illegal/recreational drug use and
had very little focus on improving the health outcomes for active drug users. Although most
efforts began as illegal initiatives, far removed from mainstream medicine, the emergence of
HIV/AIDS in the early to mid-eighties and its disastrous effects, particularly for people who
inject drugs (PWIDs) and men who have sex with men (MSM), led to a political context more
open to harm reduction initiatives. This more than anything else, helped to create a semilegitimate political space for harm reduction oriented activities (Riley et al. 2012).
Harm reduction programs have notably demonstrated reduced rates of overdose, bloodborne disease transmission and prisoner recidivism, and are also associated with high rates of
client satisfaction (Eshrati et al., 2008; Marlatt, 1996). Although harm reduction includes a
variety of viewpoints, it is largely informed by a drug-user rights perspective that sees
many/most of the harms associated with drugs as products of their illegal status and efforts on
the part of the state to criminalize individuals who use drugs. Such groups argue that recovery
and its necessary focus on drug use-as-disease obscures the role of criminalization in creating, or
greatly adding to the difficulties and harms experienced by drug users (INPUD, 2014; AIVL,
15

2012). A similar view is expressed in the Vancouver Declaration, a statement complied by druguser activists working to “enable and empower people who use drugs legal, or deemed illegal,
worldwide to survive, thrive and exert our voices as human beings to have meaningful input into
all decisions that affect our own lives” (Vancouver Declaration, 2006).
However, advocates have noted a tendency towards less radical positions in harm
reduction associated with its increasing acceptance in mainstream medicine. Although harm
reduction approaches to drug use/treatment are often seen dichotomously to abstinence-only
approaches, the recent focus on recovery has led many to call for their integration (see for
example McLellan & White, 2012; Futterman, Lorente & Silverman, 2004; Marlatt, Blume &
Parks, 2001). Such arguments acknowledge harm reduction’s acceptance of drug use as a
potential benefit towards connecting difficult-to-reach drug users with treatment, but only within
a framework that locates abstinence as the most beneficial outcome (Kellogg, 2003; Marlatt,
Blume & Parks, 2001). More radical harm reduction activists and drug-user rights groups reject
such claims as the co-opting of harm reduction’s original philosophy of accepting drug use/users
as a legitimate choice (AIVL, 2012). As the Australian Injecting and Illicit Drug Users League
points out in its analysis of harm reduction’s relationship to the ‘new recovery’ movement,
“Harm Reduction is not and can never be reduced to a ‘by the way’, ‘side thing’ we do while we
get on with the ‘real’ job of reducing the supply of, and demand for illicit drugs and getting
people on the ‘road to recovery’. Harm Reduction is about active drug use 3…. It is not, cannot
and was never meant to be a point on a ‘continuum’ towards the ‘real’ goal of abstinence and a
drug-free lifestyle.” (AIVL, 2012).

3

Emphasis not mine.
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Chapter 2 - Methods
Research Questions
1. How well do the tenets and claims of the recovery model in MMT align with the experiences
of individuals in the program?
2. How, if at all, has the shift towards conceptualizing MMT as recovery-based treatment
affected issues of agency and control among individuals in the program?
3. How does conceptualizing MMT as recovery-based treatment affect how drug use, drug
treatment, and drug control are understood?
Data collection
This dissertation is based on approximately two years of qualitative research consisting
primarily of semi-structured interviews and ethnography, as well as elements of autoethnography. This study was approved by the City University of New York (CUNY) Baruch
College Internal Review Board (IRB).
Semi-structured interviews
Semi-structured interviews were conducted with a total of 42 participants from three
populations: people on methadone maintenance treatment (MMT) (either currently or within the
previous two years) (n=23); people who work as treatment providers (individuals working at
MMT clinics and government administrative offices that regulate MMT) (n=10); and people who
work with advocacy organizations that address the needs of People Who use Drugs and people
on MMT (n=9).
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Participants were recruited using a combination of convenience and snowball sampling
based initially on contacts I had through my own experience as a drug user who is currently on
MMT. After completing their interviews, these initial participants were provided recruitment
flyers with a description of the study and my contact information, and asked to distribute them to
others who might be interested in participating. Most participants lived in the New York City
metropolitan area and I usually conducted those interviews in person, however some lived
elsewhere and in these cases, I did the interviews by phone. Eligibility criteria for participation
in the study included: ability to speak and understand English, and to understand, and provide
informed consent. Participants were paid $20 (though not every participant accepted
compensation) and interviews lasted approximately one hour, and were recorded to be
transcribed later.
Although interview questions varied by participant category, they generally addressed
participants’ experiences with, and views of, illegal drug use and treatment. Interviews with
participants from the MMT client group tended to be less structured than those with the other
groups, often taking the form of a dialogue. This was important for two related reasons. First,
people on MMT are by definition a marginalized group who are used to exercising caution in
regards to what types of information they disclose. For example, admitting to using illegal
substances or otherwise acting in ways outside of the accepted (recovery-based) behavior can
result in serious penalties including the loss of take-homes, difficulties with clinic councilors,
and even potential dismissal from the clinic. This meant that part of our conversations,
particularly early on, involved my having to gain participants’ trust.
After a certain amount of trial and error, and in cases where the participant seemed
reticent to open up, I often revealed my own status as a drug user and person on MMT.
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Although I had planned to not reveal any personal information, it quickly became apparent that
the benefits of disclosing my status, in terms of richness and quality of data, as well as the
increased honesty and comfort of the study participants, seemed to far outweigh the benefits I
might gain in terms of not “biasing” my data. For example, participants often visibly relaxed or
verbally expressed relief upon my disclosing my own history and status as someone on MMT.
Similarly, my familiarity with the terminology, common culture, and shared experiences, also
helped to position me as part of the community rather than an outsider, who are often (and with
good reason) viewed with suspicion.
Secondly, because ideologies of oppression are often internalized (Reinarman, 2005;
Gorelick, 1998; DeVault, 1996) - particularly in an institutional setting like MMT (Harris &
McElrath, 2005; Foucault, 1972; Goffman, 1968) - it is likely that participants from this group
may initially describe their experiences through the institutionally accepted narrative, regardless
of how well it aligns with their experiences and/or treatment goals. The dialogue interview
format I employed helped to create an environment where participants felt comfortable
describing their experiences in ways outside of those concepts and language. Specifically, I tried
to ask evocative questions that would encourage participants to be self-reflexive (see for example
the interview with Cheryl in Experiencing Recovery chapter). In some cases, this strategy led to
participants experiencing conceptual ‘light-bulb’ moments in regards to their own experiences.
These types of methodological concerns have been discussed extensively in Marxist and
Feminist research, which are necessarily addressing internalized power structures and the
ideologies that support them (Powers, 2001; Blume, 1998). In response, numerous feminist
scholars, particularly those working with qualitative methods, have rejected the notion of a
distanced and neutral observer, choosing a situated approach to knowledge instead (DeVault,
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1996; Haraway, 1988). Situated approaches are those that acknowledge the positionality and
power relationships existing between researcher, subject, and participant. They are most often
used when studying groups that are structurally and ideologically marginalized, and generally
place a greater emphasis on transparency and reflexivity than on neutrality and objectivity.
Situated approaches to research are also more comfortable with the political and activist
concerns of research, in that challenging power is seen as a valuable part of the process
(DeVault, 1996). Addressing these tensions, feminist scholar Marjorie L. DeVault writes that
they “provide the outline for a possible alternative to the distanced, distorting, and
dispassionately objective procedures of much social research.” (1996; p. 29).
However, conducting social research as an insider also involves a number of challenges,
some that are specific to the researchers’ insider status (Burns et al. 2012; Humphrey, 2013).
Most prominent in this study were ethical challenges that arose when interviewing participants
who were clearly experiencing pressure and guilt related to recovery’s demands on them –
particularly in regards to the necessity of complete abstinence. For example, some participants
described instances of having been pressured and/or punished by their clinic for non-opioid (or
sometimes opioid) drug use, which they would describe as being ‘their own fault’, often
demonstrating significant distress over what they saw as a personal failure. My ‘gut reaction’ to
these situations was to let them know that I did not necessarily see a problem with their behavior
and that their clinic difficulties could be just as easily understood as the result of the unfair, and
impractical demands of MMT’s recovery culture and structural organization. This feeling was
even stronger because of my own position of power as a doctoral student who is also a drug user
on MMT - this meant that participants not only invested certain amount of pride and respect in
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my accomplishment, but also that they assumed (incorrectly) that I was now in recovery and
abstinent from illegal drugs.
Although I refrained from disclosing my political views on recovery and other subjects
that were directly related to the study, I did attempt to create an atmosphere where participants
felt free to describe experiences that contrasted with the dominant discourse. For example, if,
during an interview, I got the feeling that a participant was conflicted or clearly parroting the
clinics’ view on the disease model rather than her own, I might say, “You know, not everyone
thinks of their drug use as a disease, it’s ok if you see it differently.”
Thus, Marxist and feminist literature (Naples, 2003; DeVault, 1996; Haraway, 1988)
served as a helpful guide to the types of issues that came up in this study, and I tried to adopt its
situated, self-reflexive, and flexible approach. Similarly, I viewed each situation as both a
negotiation and a learning process, where I attempted to balance the oft-competing values of
research, activism, and a concern for the individual study participants, who are dealing with
structural issues that I also have a personal and political stake in.
Despite the many challenges, I am confident that my insider status enabled me to gather
data that would have been very difficult, if not impossible for someone without direct experience
in this community. Moreover, I believe that most participants from the MMT-client group (the
most clearly marginalized group) enjoyed discussing these topics. People who use illegal drugs
are so often used to having their own lives and experiences framed by other, more powerful
groups and actors that many expect to have little meaningful input in scholarly research. Rather,
their experiences are generally flattened to produce quantitative representations of pathology like
the number of overdoses they have experienced or the number of substances they have consumed
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in a given time period. Hence, I believe that most participants (from the MMT-client group)
found it refreshing to be asked about their own views of drug use and drug treatment.
Ethnography
Ethnographic observations were carried out primarily at the methadone clinic I attend in
The Bronx, NY. I am at the clinic once every four weeks for a period ranging from 1 to 3 hours,
and used this time to make field observations and notes. Since methadone clinics are often
highly bureaucratic spaces that are also designed to protect their clients’ anonymity, I felt that
this strategy would be much easier than to try gain approval for ethnographic research inside of a
clinic I had no relationship with. The clinic I attend is a large and bustling place with clients
involved in multiple activities including: meeting with councilors, getting medical exams, or
waiting around either to ‘dose’ 4 or to meet with their counselor. Thus, my visits often included a
significant amount of ‘down time’ where I was able to talk with other clients and employees, and
observe the general activities. Additionally, individuals who attend this clinic (and many clinics)
often congregate outside after dosing, both for social reasons, and sometimes to participate in
illegal drug deals. I usually spent 10-20 minutes there to get a sense of participants’
conversations outside of the immediate clinic environment.
In addition to my regular visits to my own clinic, I was also able to visit approximately
five other methadone clinics in New York City. These visits took place while interviewing clinic
staff, owners, and/or administrators, who would sometimes provide me with a tour of the
facilities which often included conversations with other clinic staff and clients. Although the vast
majority of my ethnographic data was obtained from my own clinic, visiting other clinics, even if

4

“Dose” is the nearly ubiquitous term among people on MMT for obtaining their daily dose of methadone.
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for a short period of time, provided an important context for determining differences and
similarities among New York City (NYC) methadone clinics.
Auto-ethnography
Finally, this research is informed by my own experiences as an illegal opioid (primarily
heroin) user and as someone currently on MMT. I have been on MMT for approximately 11
years and received services at two clinics: one in Chicago, IL and currently in The Bronx, NY.
Although I do not refer to my own experiences directly as data in this paper, they have
structured my own views on this topic and, correspondingly, the direction of this study. Thus, it
incorporates elements of auto-ethnography. As discussed in the Interview section of this chapter,
my direct experience as someone whose used drugs was, for the most part, highly beneficial
throughout the data collection phase of the project. I not only had access to a hard-to-reach
population, but as a fellow person who uses/d drugs, I was also afforded a much greater level of
trust than an outsider would likely have been given. Yet, it also led to a number of
methodological challenges (also discussed in the Interview section).
Data Analysis
Although the data analysis portion of the study did not employ a specific coding strategy,
it was guided by themes I had developed through my own 11 years’ experience in MMT. Thus,
while this study was not deductive, or based on hypothesis testing, I did begin the study as
someone who was aware of many of the potential issues involving recovery in MMT.
I began the analysis process by repeatedly listening to participant interviews in order to
develop some basic ideas as to how well the data aligned with my own knowledge and
experience. As I listened to, transcribed, and thought about the data, I began to develop a series
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of concepts and themes that I used to organize the data. This was not a rigid coding structure but
rather, a set of emerging themes and notes. I also made attempts to test themes by seeking out
alternative cases and potential explanations in the data.
Theoretical position:
The data analysis portion of this study was also guided by a variety of anti-positivist and
post-structuralist theoretical positions. Interview data in particular focused on the tenets of
Foucauldian discourse analysis (Foucault, 1972). In “Discourse Analysis and the Critical Use of
Foucault” Linda Graham distinguishes Foucauldian forms of discourse analysis by their concern
with power, representation, and a reticence to see method as an objective means of uncovering
“truth” (Graham 2005). Although Foucault avoided delineating a specific methodology, his
work consistently focused on the “constitutive and disciplinary properties of discursive practices
within socio-political relations of power” as a way of illuminating “how language works not only
to produce meaning but also particular kinds of objects and subjects upon whom and through
which particular relations of power are realized” (Graham 2005: 4). Thus, by applying a
Foucauldian perspective to the emergence of recovery in MMT, my project focuses on how the
recovery discourse creates particular types of objects (for example, those in recovery or those not
in recovery) who are then subjected to particular practices that are also delimited as part of the
discursive project of recovery.
Thus, this study is grounded in a larger epistemological tradition of social
constructionism (Berger and Luckman 1966). In The Social Construction of Reality, Berger and
Luckmann argue that all knowledge is a product of social interactions whereby groups and
individuals create concepts that inform and give meaning to their reality (1966). Over time,
dominant ideas become embedded within society’s institutions, thereby appearing to exist
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objectively and distinct from the social and historical circumstances that led to their formation
(1966). Based on this view, termed Social Constructionism, ideas are not seen as trans-historical
or maintaining an essential quality, but rather are generated within a specific social and historical
milieu (Berger and Luckman 1966; Conrad and Schneider 1991). Numerous scholars have
applied these concepts to studies of scientific and medical knowledge detailing the role of social
construction in areas generally thought to be objectively determined (see for example Rothman
1982; Smith 1990; Metzel 2009; Dingel et al. 2011). These studies demonstrate that contests
over knowledge and meaning have significant effects for individuals and society, and to
understand how knowledge is produced in this context, scholars must adopt a critical perspective
that aims to deconstruct knowledge discourses in order to “expose the workings of assumption,
commonsense and intuition.” (Brook and Stringer 2005: 317).
Similarly, this study adopts a deconstructivist approach to understanding textual data
(Derrida, 1976). In the preface to On Deconstruction, Jonathan Culler, following Derrida, writes
that Deconstruction is not “a school or a method, a philosophy or a practice, but something that
happens, as when the arguments of a text undercut the presuppositions on which it relies”. (p. 2)
Thus, at its core, Deconstruction is a means of thinking critically, and of interrogating rather than
immediately accepting, the concepts that comprise an argument. This approach was particularly
useful in regards to studying this topic since drug use and treatment culture is rife with concepts
that are discursively positioned as objectively true or objectively good - even ‘recovery’ itself is
constituted, both linguistically and within the social context of drug treatment, as an inherently
‘good thing’. Using interview data to critically interrogate, or deconstruct the recovery discourse
in MMT, offers a way of challenging such assumptions.
The phenomenon in MMT
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Finally, this paper also adopts Fraser and Valentine’s theoretical framework based on
challenging narratives that conceptualize MMT through reductive and essentialist lenses (2008).
Fraser and Valentine borrow from feminist science and technology studies, in particular the work
of Karen Barad, by framing methadone as a phenomenon, described as “an assemblage of human
and non-human actors made in its encounter with politics, culture and research” (2008: p. 3).
This approach allows for an analysis of MMT that acknowledges both the material and the
social/cultural/discursive, and sees the two as co-constitutive. In Barad’s model, the
phenomenon replaces the notion of bounded and distinct objects with definite properties, thereby
problematizing standard notions of causality that imagine a linear chain of objects, each one
produced by its predecessor (Barad, 2003; Fraser & Valentine, 2008). Here methadone the
substance, treatment regulations, and the political climate they exist within are all seen as related
to, and co-constructing one another. This position is particularly useful in regards to studying
drug use and treatment which have typically been conceptualized through overly deterministic
narratives that focus primarily on individual bodies using substances at the expense of the
(political, social, structural) context that drug use and treatment occur within.
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Chapter 3 Producing recovery: A shift towards constructing the un-walled prison

“Recovery encompasses an individual’s whole life, including mind, body, spirit, and
community.” (SAMHSA, 2012)

Recovery is a view of overcoming addiction that sees abstinence as a prerequisite, but
also incorporates a larger, more general conception of wellness, as well as social and metaphysical aspects of an individuals’ life such as spirituality and community involvement. It
involves a fundamental shift in how drug treatment services in general, and methadone
maintenance treatment (MMT) specifically, are understood, administered, and experienced.
Thus, the institutional focus on framing MMT as a recovery-based treatment represents a new
form of governance that requires people who use drugs (PWUDs) to undertake projects of total
self-reconstruction aimed at revealing a healthier, more authentic self.
Background
Individuals involved with the administration of methadone maintenance treatment
(MMT) spoke a great deal about the push by government organizations like the Substance Abuse
and Mental Health Services Administration (SAMHSA), the Office of National Drug Control
Policy (ONDCP) and the New York State Office of Alcoholism and Substance Abuse Services
(OASAS) 5 to base their treatment models on recovery. The shift was seen as an important
change in how drug treatment services were being conceptualized and administered. As Robert
Lubran, SAMHSA’s Director of Pharmacologic Therapies explained:

5

New York state is the location of this study.
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“I saw this [recovery] starting to trend maybe five or six years ago…. And it
started catching on here favorably and has continued, and I think will continue to
expand as we see the benefits of it and encourage programs to understand how
that can be beneficial to patients.” (Lubran, 2014).
Lubran’s comments are corroborated by the extensive efforts on the part of government
to promote recovery as the focus and lynchpin of substance use and mental health treatment
services. In 2010 ONDCP established a recovery branch whose purpose is to engage with
federal, state, and local government, as well as advocacy organizations, service providers, and
stakeholders with the goal of developing policies, programs, and campaigns that support longterm recovery (ONDCP, 2015). Similarly, in 2010 SAMHSA “issued 30 new Access to
Recovery (ATR) grants to 23 states, 6 tribes, and the District of Columbia. Funded at $98.9
million annually over 4 years, this program expands treatment and recovery support services that
are critical to sustaining recovery” (ONDCP, 2015). According to their Recovery Oriented
Systems of Care (ROSC) guidebook SAMHSA states: “The adoption of recovery by the
behavioral health systems in recent years has signaled a dramatic shift in the expectation of
positive outcomes for individuals who experience mental health and substance use conditions”
(SAMHSA, 2010) and that “Recovery has been identified as a primary goal for behavioral health
care” (2015).
Although most administrators admitted that there are many definitions of recovery, and
in-fact stress that the model is about individualized care, they also described recent attempts by
both government and advocacy organizations to create a unified understanding of what recovery
means. Many referred to a 2006 meeting convened by the Betty Ford Institute (BFI), where
recovery was defined as “a voluntarily maintained lifestyle characterized by sobriety, personal
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health, and citizenship” as an early attempt to operationalize the developing ideas behind
‘recovery’ (The Betty Ford Consensus Panel, 2007). SAMHSA and OASAS administrators
explained that BFI’s conception was important because it located recovery as distinct from
abstinence. Although abstinence from all illegal substances was considered a prerequisite,
recovery was seen as a totalizing process that went beyond the discontinuation of certain types of
substance use.
Specifically, administrators and treatment providers described ‘recovery’ as diverging
from previous treatment models in three ways: 1. Recovery reflects a trend towards eliminating
conceptual distinctions between mental health and substance use issues, as well as between
different types of substance use issues and treatment models. 2. Recovery is based on a medical
(disease-based) understanding of drug use problems (addiction) 3. Recovery is based on a view
of substance use problems (addiction) and their treatment as encompassing all aspects of the
individuals’ life.
Technologies of Power (governmentality)
Foucault’s conception of governmentality, though not entirely operationalized, is helpful
towards understanding how recovery discourse functions within MMT. Governmentality,
sometimes understood as technologies of power, describes the wide range of control techniques
aimed both at controlling the self and towards the large scale management of populations
(Foucault, 1991). Nickolas Rose writes that technologies of power are those “imbued with
aspirations for the shaping of conduct in the hope of producing certain desired effects and
averting certain undesired ones" (Rose, 1999). For Foucault, Technologies of Power are always
contextualized through historically situated forms of knowledge, or regimes of truth, that
function as their own form of power (power-knowledge). As such, MMT as constituted through
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recovery discourse, functions as a technology of power that produces certain kinds of people.
Helen Keane writes in “What’s Wrong with Addiction”, that recovery discourse “translate[s] the
enigmatic desires and dissatisfactions of the individual into precise ways of inspecting oneself,
accounting for oneself, and working upon oneself in order to realize one’s potential, gain
happiness and exercise one’s authority” (Keane, 2002). Thus, power functions not only through
overt constraint, but through producing new ways of being that are often experienced as free
choices (though they are still forms of constraint). Keane argues that medical categories are
particularly imbued with this type of power:

“Therapeutic authorities work in the service of liberty and personal choice, which
ironically makes them more profoundly subjectifying than other more obviously
oppressive forms of authority. Therapeutic authorities seem to emerge from inside
ourselves, from our desires for happiness and striving for fulfillment. The
understanding of freedom as a regulative norm provides a useful insight into
recovery discourse, which urges troubled individuals to attain autonomy and find
happiness through open-ended projects of self-examination and selfimprovement” (Keane, 2002)

1. All Pathways lead to Recovery

The focus on recovery by government agencies is part of an effort towards
mainstreaming substance use disorders and treatment alongside other issues conceived of as
mental health problems. SAMHSA and OASAS administrators felt that in the past substance use
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disorders had been seen as fundamentally different from more traditional mental health problems
leading to increased levels of marginalization and stigma for patients, treatment providers, and
drug treatment services in general. Moreover, within substance use treatment, conceptual
distinctions existed between programs using medication-based versus those using “abstinencebased” treatment, defined here as programs that do not use medications as part of treatment
(usually methadone or buprenorphine), such as 12-step groups or therapeutic communities 6.
The new model positions recovery as the overarching goal for all substance use and
mental health disorders, and differences in treatment choices are seen as individual pathways
towards it. Thus, everyone is ostensibly pursuing the same outcomes as defined by the recovery
model. As SAMHSA’s website explains:

“The process of recovery is highly personal and occurs via many pathways. It
may include clinical treatment, medication, faith-based approaches, peer support,
family support, self-care, and other approaches” (SAMHSA, 2014).

An individualist approach?
SAMHSA and OASAS administrators as well as local treatment providers actively
promoted recovery as being an individualist model, describing it as “less of a cookie-cutter
approach” and as a program that “the individual gets to define”. However, this tended to apply
only to decisions regarding ‘how’ to pursue recovery, and not to patients’ views on the overall
desirability of ‘recovery’ as a treatment goal. The ability of patients to exert agency over how

The term ‘abstinence’ is used in wide variety of contexts and its meaning can vary substantially. When referring
to treatment programs, ‘abstinence-based’ can often mean 12-step programs like Narcotics Anonymous (NA) and
Alcoholics Anonymous (AA) that reject the use of medications, contrasted against programs like MMT.
6
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their treatment was conceptualized or the overriding treatment goals, depended on whether, and
to what extent, their views corresponded to the tenets of the recovery model. For example,
administrators stressed that recovery could be pursued in a myriad of culturally appropriate ways
and that characteristics such as race or ethnicity, religion, gender, mental health, disability,
sexual orientation or gender identity should ideally inform a patients’ recovery plan. However,
when asked how the clinic would respond to patients whose goals conflicted with the recovery
ideology – such as those who see MMT as a way to use less drugs or use drugs more safely (i.e.
legally) – responses ranged from overtly punitive (the patient would be disciplined until
eventually kicked out) to covertly punitive (counseling as to the ‘rightness’ on abstinence,
disease model, etc.).
Some acknowledged the usefulness of harm reduction as a means of reaching out to
patients or keeping them involved with treatment, and stated that a certain amount of drug use
would be tolerated early in the patients’ treatment, but it was always framed as a deviation rather
than part of the patient’s intended path. Others rejected harm reduction outright and relied upon
discourses that position “the addict” as someone incapable of self-control or acting in their own
best interests to justify this position. For example, when asked about patients who see MMT as
a way of gaining stability and control over their lives without becoming abstinent, one treatment
provider responded:
“That’s just a lie you want to tell yourself, ‘that you just want to get it [drug use]
under control’ because as an addict, and I know people don’t like the saying ‘once
and addict, always an addict’ but as an addict, that’s the issue, the control, you
can’t keep it at that [safer or more controlled drug use]. As an addict, the minute
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that you have that problem at work or your boss reprimands you, what you’re
using is gonna double. That’s just the way it is. (Bigitschke, 2014)

Thus, patients who see their treatment as a means towards achieving recovery as defined
by the dominant discourse, were free to pursue it through a variety of culturally appropriate
strategies. However, those who conceptualize their treatment as a form of harm reduction – or in
any way outside of the recovery discourse – were seen by treatment providers either as liars and
self-deceivers, or as not yet ready for recovery, which was always seen as the true purpose of
treatment.
MMT as the most stigmatized
The focus on inclusivity is particularly relevant in regards to MMT since one of the
central distinctions within the substance use treatment community involves the legitimacy of
MMT as a treatment and/or form of recovery. Since MMT is often seen as fundamentally
different from treatment programs that do not use medications (such as 12-step groups),
individuals on the program have typically battled the view that they could not identify as being in
recovery because they were taking methadone. Administrators believed that the focus on
recovery as a universal among individuals with substance use and/or mental health issues would
reduce this distinction. Belinda Greenfield, OASAS’s Director of Addiction Medicine & Self
Sufficiency Services explains:

“Greenfield: Specific to methadone, it’s kinda fragmented… I think there’s been
a lot of gains made over the recent years about people talking about their recovery
from addiction but not as often do we hear about people’s recovery from
addiction using medication, and using methadone specifically. So when you
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listen to recovering peoples’ stories oftentimes there is no medication involved to
treat the addiction. Or you may hear ‘I was in a methadone program but now I’m
no longer in a methadone program, and I’m drug free.

Frank: So methadone wasn’t considered a form of recovery?

Greenfield: Right. And the way we speak about recovery and what we don’t say
in relation to recovery, like for instance I may be in recovery and not share that
I’m on an addiction medication for fear of being stigmatized. We omit that
information or we don’t even bring it up or don’t include them, individuals that
are doing well but on an addiction medication as a part of them doing well. That
signifies that they’re a part of the recovery community…. It is an important piece
for New York State to try and bridge that gap, to recognize that the use of
medications is another recovery path. It’s no better or worse than the ‘drug-free’
path. Actually, for myself, I try to remove the language around ‘drug-free’ versus
methadone maintenance because again it creates a hierarchy, it creates a
differentness. There shouldn’t be that kind of thinking that says one person’s path
to recovery is better than another’s. (Greenfield, 2014)”

2. Recovery is based on a medical conception of addiction

Administrators from SAMHSA and OASAS as well as clinic counselors and treatment
providers clearly stated that their respective organizations view addiction as a disease and that
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encouraging clinics and patients to adopt this view were essential parts of the organizations’
mission to promote recovery. As Greenfield states:
“[The disease model of addiction] definitely for OASAS is first and foremost.
That’s how we reference it. That’s how we label it. That’s how we position
ourselves and how we position the treatment services, is that ‘you need to
consider this as a chronic disease and look at it through the lens of a chronic
disease’.” (Greenfield, 2014).

Administrators’ use of language also revealed a focus on presenting addiction within a
medical context. Problematic drug use was consistently described as a “disease”, “disease-like”,
or as a “medical issue”, and medical terminology such as “relapse” and “remission” was used to
describe drug use events. Similarly, some administrators and treatment providers employed
analogies between addiction and diseases like Asthma or Diabetes – which often require lifelong
use of medication – to explain why being maintained on methadone does not disqualify patients
from the recovery label.

The Politics of Definition
Health and Illness scholars have used constructionist frameworks to argue that the
designation of behavior as “medical problems” or “diseases” is an inherently political act that
carries with it a set of fixed identities, power relationships, and codes of behavior (Conrad, 1980;
Zola 1972; Foucault 1988). As Conrad, who called this process the “Politics of Definition”
pointed out, “Medical work can lead to the creation of new norms whose violation is deviance,
or….. new categories of illness. This increases the jurisdiction of medicine or some segment of it
and legitimates the medical treatment of sick deviants.” (Conrad, 1980, p. 23). Thus, the
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institutional designation of certain forms of drug use as addiction, and addiction as a disease,
explains the actions of the clinic through the logic of treatment. Disciplinary actions, intrusive
forms of monitoring and surveillance, and the imposition of an ideology that may conflict with
patients’ own views, are all seen as necessary and for the patient’s own good. Individuals who
may conceptualize their relationship to MMT in ways outside of those delineated through the
medical discourse – for example, those who see MMT as a harm reduction strategy for
avoiding/minimizing their exposure to the forces of criminalization, including problems such as
disease transmission or withdrawal; or those who see MMT as a way of stabilizing their lives
without the attendant focus on disease and recovery - are positioned in opposition to the
dominant ideology and likely to encounter increased levels of surveillance and discipline.
Although addiction-as-disease narratives are generally supported through appeals to
science, post-structuralist and feminist science scholars (among others) have problematized
notions of science as objective, linear, or trans-historical. They argue instead, that science is a
historically situated narrative, based on specific epistemological practices, and socially
constructed in much the same way as other forms of knowledge (Foucault, 1973; Barad, 2014).
Moreover, health and Illness scholars have pointed out the political efficacy of scientific
narratives, arguing that because science is associated with notions of objectivity and truth, the
designation of a narrative as ‘scientific’ conveys significant cultural capital (Reinarman, 2005;
Keane, 2002). Craig Reinarman demonstrates this in “Addiction as Accomplishment: The
Discursive Construction of Disease” by pointing out the organizational push by Alcoholics
Anonymous (AA) (and others) to “popularize the disease concept by putting it on scientific
footing”, noting that “science was not the source of the concept but a resource for promoting it”
(2005: 313).
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Rienarman also uses social learning theory to examine how addiction-as-disease models
are taken up by individuals entering treatment (Rienarman, 2005; Weinberg, 2000). Such
individuals - who enter treatment either through state compulsion or “voluntarily” 7 - must adopt
a particular frame of reference for understanding their drug use based on addiction-as-disease
narratives. Echoing Goffman, Foucault, and Szasz, Reinarman’s account illustrates how
treatment is often structured to reward and punish individuals based on their willingness to
accept the institutional narrative (Reinarman, 2005; Goffman, 1968; Foucault, 1973; Szasz,
1961). “Addicts” participate in a performative process where they learn to describe their newly
reconstituted life stories utilizing the linguistic rules of disease discourse. While not denying the
lived experience of drug users in treatment, Rienarman argues that “What are taken to be
physiological-pharmacological effects do not present themselves to users in some raw, precategorical form, without the linguistic encasements provided prior to ingestion by culture
(Reinarman, 2005: 316). Thus, addiction-as-disease narratives are re-produced both
institutionally and through individual accounts, which are themselves co-constitutive of one
another.
Obscuring Structures
Scholars have also recognized that the tendency for disease narratives to focus on the
individual as the site of intervention necessarily obstructs the role of structural factors (Clark,
2014; Reinarman & Levine, 1997; Crawford, 1980). According to the logic of the disease
model/recovery narrative, the problems that brought individuals to MMT are strictly the result of
their disease, addiction, which – whether conceptualized as biological, spiritual, or behavioral (or
a combination thereof) – conceives of the problem as an individual one. The contextual reality
The contextual reality of prohibition and the war on drug users complicates notions of volition in regards to
individuals entering substance use treatment.

7
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of prohibition as a force of harm in illegal drug users’ lives, and one that drives them towards the
relatively safer space of quasi-legal opioid use within MMT is obscured from the model. Thus,
the recovery narrative implicitly supports prohibition by reifying the belief that drug use
problems are the result of individual level diseases and not related to how the state polices
substance use/ers, thereby justifying a variety of medico-punitive responses to illegal drug use
including MMT.
The designation of MMT’s function as the medical treatment of addiction is also
problematized by the many alternate narratives that conceptualize the program differently. Harm
reduction advocates, drug user rights groups, and others have focused on the pragmatic benefits
of MMT including reduced rates of prisoner recidivism, reduced rates of blood-borne disease
transmission, and as a means to stabilize one’s life (Joseph, Stancroft and Langrod, 1999;
Drucker et al. 1998; Langendam et al. 2001). A study of individuals on MMT in the UK found
that while the majority of people on MMT are seeking abstinence, significant numbers report
‘reduced drug use’ and ‘stabilization’ as their primary treatment goals (Mckeganey et al. 2004).
Moreover, social theorists like Chris Smith have used anarchist concepts like autonomous
zones, to argue that harm reduction efforts provide criminalized groups with spaces (physical,
ideological, etc.) that exist outside of the dominant power structure (2012). He cites
underground crack kit distribution, peer-based naloxone distribution, and illegal Safe Injection
Facilities (SIFs) as examples of harm reduction’s true anarchist spirit, thereby problematizing
clear-cut notions of rule breaking and rule following for criminalized groups and individuals.
Smith’s approach is important since it recognizes the many ways that criminalization and the
War on Drug Users complicates notions of freedom and volition for drug users in treatment,
pointing out that harm reduction is, at its core, an attempt to carve humanizing spaces out of a
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punitive landscape. In this context, MMT is not necessarily (or only) a place of treatment, but a
refuge where drug users can avoid the harmful consequences of criminalization and experience
greater levels of agency of over their drug use choices. Behaviors such as faking a drug tests to
avoid dismissal, which are seen as rule-breaking or even crimes by the recovery discourse, are
re-cast by Smith as manifestations of survival and resistance in a regime that actively targets
drug users (2012).

Describing the disease
Reflecting the varied and complicated landscape of substance-use-as-disease models,
participants drew upon a combination of disease theories to describe addiction. Although some
were based in part on the neurological disease model advocated by the National Institute of Drug
Abuse (NIDA) that conceives of addiction as a neurological pathology, most accounts reflected a
more behavioral, spiritual, and metaphysical view. Typically when neurological models were
invoked, participants supported their views with references to science that positioned current
treatment practices as the product of technological advances which have finally revealed the
truth about addiction and its proper treatment. As one clinic director explained “With the newer
science, with imaging, and things like that, seeing how the brain actually does change, there’s a
lot more scientific consensus that addictive behavior over time changes the actual way the brain
works.” (Sheerin, 2014). Yet, as the interview continued, his view diverged from the classic
neurological understanding of addiction as a chronic, lifelong condition towards a model that
better incorporated the possibility of recovery8, stating “However, the biological, medical piece
of permanence of condition which necessitated the belief that people had an addiction for life has
It is unclear whether the participant was referring to recovery as the eventual cessation of methadone
maintenance or if he was including individuals maintained on methadone as being in recovery.

8
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changed over the years because of the finding that in certain types of addictive or dependent
behavior, people do enter recovery for extended periods of time.” (2014).
Most treatment providers’ responses reflected a view of addiction that is primarily
behavioral and spiritual, rather than pharmacological. For example, Larry Taub, Director of
residential services at the Lower East Side Service Center, stated:

“Recovery is a productive lifestyle that’s not drug involved. All of the things that
the Big Book would say is recovery we would say is recovery…. [Spirituality is]
going deeper into something that’s beyond your narcissism, tapping into
something. I say for folks that are kind of atheistic or not open to that I say
‘We’re your higher power. The therapeutic community is your local higher
power.’ It’s investing in a community instead of your narcissistic drug taking
behavior. If you can buy into that as a higher power, trust our rules and
regulations, trust our staff, like being here or can tolerate being here, well maybe
that’s a higher power than the arrogance of your addiction” (Taub, 2014)

However, Taub, despite this view of addiction, still utilized the neurological disease
model as a tool for moderating addicts’ shame and encouraging individuals to pursue recovery.
He explained:
“We accept that there is a brain disease, but we’re not intervening in the brain.
We’re intervening at the level of behaviors, of attitudes, of spirit. Of course all of
that’s the brain, but… we discourage talk of neurotransmitters…. Really what you
have to do is people, places, and things, and triggers to relapse, and anger
management, and that kind of stuff…. I think it’s [the neurological disease model]
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an incorrect way to talk, but I find it’s absolutely critical for the following reason,
and ok for the following reason, that one of the reasons [that] people don’t
approach recovery is shame and guilt. If you allow the disease concept talk to
happen, it mediates shame and guilt and removes a barrier to getting to
treatment.” (Taub, 2015)

Treatment providers also utilized a number of themes and concepts associated with 12step groups to understand and explain the disease of addiction. Concepts like the ‘dry drunk’ are
traditionally associated with 12-step groups’ and speak to addiction as a spiritual and behavioral
‘disease of the will’ rather than a neurological disorder. Similarly, the importance of community
and self-reconstruction, which fit more easily within a behavioral model, also attest to the
amalgamated and slippery character of recovery discourse within MMT.
“I don’t consider someone in recovery on the sole purpose that they’re not using,
because there’s such a thing as a ‘dry drunk’, somebody who’s not using but is
engaged in all of the behaviors of addiction… I would call that, they’re staying
away from substances but that they have some steps in their recovery to focus on,
like for example, not engaging in criminal activity.” (Vick, 2014)

Reinarman (and others) have addressed the particularly amorphous character of
addiction-as-disease discourse, calling the history of disease theories of addiction a “conceptual
acrobatics” (2005). It is this difficult-to-pin-down quality, he argues, that makes addition-asdisease narratives so easily applied to a variety of seemingly unrelated phenomenon, that now
includes shopping, love, gambling, internet use, and the need for human contact. Yet, even when
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focusing on drug use alone, Reinarman argues that “the complexities of drug-using behaviors
continue to defy rigorous categorization under the heading of addiction-as-disease” (2005).

The role of Stigma

The use of the disease model as a conceptual scheme for understanding addiction was
seen by many as a strategy for reducing stigma attached specifically to methadone within the
drug treatment community. Thus administrators echoed a common claim among MMT
advocates within the recovery movement that if addiction were accepted as a disease, methadone
would be better accepted as treatment. A SAMHSA administrator explains:
“When they start seeing it as an illness, and like all other illnesses have
medication attached to it, that help people to get better, then they start talking
about the different pathways to recovery, and one of those pathways is medication
assisted treatment” (Wilma, 2014).

Scholars have been critical of claims that medicalization can liberate behavior from
morally-based forms of stigma, arguing that biomedical models of causation encourage
essentialist thinking (Haslam, 2011; Phelan, 2005), and can lead to stereotyping and prejudice
(Bastian and Haslam, 2005). In a meta-analytic review of biogenetic explanations’ effects on
stigma, Kvaale, Haslam & Gottdiener found that medicalization does not cure stigma and may
create barriers to recovery by setting the stage for a self-fulfilling prophesy (2013). Moreover,
scholars focused on the medicalization of drug use (and other behaviors) have problematized the
binary that positions medical and moral approaches to deviance as dichotomous, with medical
models generally seen as progressive in contrast to moral models which are viewed as punitive
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and conservative (Tiger, 2012; Reinarman, 2005). In her study of Drug Courts - a program
based on a “medical model” and often cited as a progressive policy response to addiction Rebecca Tiger demonstrates how the medical and moral/punitive models are often more
collusive than oppositional (Tiger, 2012). Similarly, Nancy Campbell argues that recovery
discourse positions those unable or unwilling to adopt it’s tenets as “embody[ing] a threatening
moral contagion” (p. 243) and Reinarman points out that “addiction-as-disease has just as often
been a discursive weapon wielded by a state that has declared war upon citizens who ingest
disapproved substances” (317).
3. Recovery is all-encompassing
“Although sobriety is considered to be necessary for recovery, it is not considered as sufficient.”
(The Betty Ford Institute Consensus Panel, 2007)

Administrators and clinicians as well as government websites and educational materials
stress that recovery is about much more than the discontinuation of substance use. Reflecting the
addiction-as-disease narrative that sees addiction as multi-faceted problem of the self that
involves biological as well as moral, spiritual, and behavioral issues, the concept of recovery is
equally totalizing. Specifically, treatment providers and administrators focused on community,
spirituality, and a general sense of morality to describe the extra-abstinence aspects of recovery:
“Part of the recovery process is for you to become part of the community, [and]
for you to become a part of the community, you can’t just go and get your
methadone, go back home and sit there. [So] how do we set you up to be a
meaningful part of the community? That’s a critical part of recovery’ (Wilma
from SAMHSA, 2014).
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In line with this shift, SAMHSA and OASAS’s recently adopted the term “Opioid
Treatment Program (OTP)” to replace a variety of other terms that focused more specifically on
methadone. The new acronym positions methadone maintenance as just one of the many aspects
of a comprehensive Opioid Treatment Program:
“We’re moving now to saying Opioid Treatment Program, Opioid Treatment
Services because we want to take away the ‘Methadone’ label. You call it
‘Methadone Treatment’ [and] it sounds like that’s all that happens is that people
drink their methadone. If we call it Opioid Treatment, they have medication, it
could be Methadone, it could be Buprenorphine. But we [also] have a whole
comprehensive array of services. One of our things is removing all of that ‘MTP’,
‘MMTP’, ‘Methadone Maintenance’, ‘Methadone Treatment Program’. It’s
‘Opioid Treatment Program’ or ‘OTP’ and the Feds have that too.” (Greenfield,
2014).

A normative construction
Based in part on the BFI’s 2006 definition, SAMHSA has established a working
definition of recovery as “a process of change through which individuals improve their health
and wellness, live a self-directed life, and strive to reach their full potential” (SAMHSA 2012) 9.
Here, recovery is comprised of four major dimensions: Health; Home; Purpose; and Community
that reflect normative conceptions about proper ways of living and how bodies should function.
For example, SAMHSA’s definition of Purpose as “Meaningful daily activities such as a job,
school, volunteerism, family caretaking, or creative endeavors, and the independence, income,
and resources to participate in society” (SAMHSA, 2012) is not only based on the assumption
OASAS’s website offers a similarly all-encompassing definition insisting that recovery “goes beyond abstinence
alone to include a full re-engagement based on hope, resilience, health and wellness, and includes family, friends
and community. Recovery starts when a person begins to make better choices about his or her physical, mental
and spiritual health.” (OASAS, 2015)
9
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that activities such as volunteering or maintaining a job are meaningful activities that reflect an
individual’s purpose, but also obscure the hierarchical reality of our society where access to
income and resources are unequally available. Similarly, Health is presented here as an
uncomplicated and universal concept, rather than a reductive and normative one that can be
made to support any number of lifestyle choices included using, or not using drugs (Keane;
2002). SAMHSA’s focus on home, purpose, and community also reflect a particular set of
(neoliberal) values that position the drug treatment services user as a consumer, decontextualized
from structural constraints, who should desire the ‘right things’ as established by the recovery
discourse.

The emergence of the Unwalled Prison

The treatment culture’s focus on the whole person can be seen as a modern iteration of
what Erving Goffman called the “Total Institution” (Goffman, 1968) 10. Goffman used the term
to describe mental institutions (as well as other confined places) that control all aspects of their
inmates’ lives. Total Institutions subject their charges to a highly regimented system of
scheduling and regulation based upon the official aims the institution, and intended to remove
their sense of self and individuality, ostensibly to be re-configured as someone who “will
maintain the standards of the establishment of his own accord after he leaves the setting” (1968).
Thus Total Institutions were places where individuals classified as deviants, could be re-made
according to normative standards. While Goffman’s description is largely focused on aspects of
spatial constraint reflecting the physical removal of the ‘mentally ill’ that was common before

Szasz, Foucault and others have used similar models to critique the medical establishment’s ability to constrain
individuals both physically and ideologically (power-knowledge).
10
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deinstitutionalization, much his focus on surveillance, regimentation, distinct social roles and
power imbalance, applies to the world of MMT under recovery. Individuals are broken down, or
mortified, in order to create “‘good patients’ who are dull, harmless and inconspicuous”. (1968).

A changing clinic culture
The emphasis from federal and state agencies on recovery as an all-encompassing
treatment model has led to changes in the clinic culture as well as in the services they are
expected to provide. One of the biggest changes involves the clinics’ increasing concern with
monitoring their patients’ non-opioid drug use 11. Although clinics have some amount of latitude
regarding what drugs to test for and how to handle failed drug screens, the recovery discourse
positions all forms of substance use, or behaviors thought to be related to addiction more
generally (gambling, ‘co-dependent’ relationships, etc.), within the clinics’ mandate and
jurisdiction 12. Punishment for non-opioid drug use nearly always results in patients being denied
takehomes, but can also be used to justify discharging otherwise compliant individuals despite
evidence demonstrating that most discharged patients do poorly (Knight et al. 1996). When
asked if patients were allowed to smoke marijuana and remain in the program, Jeffery Sheeran
from Montefiore Medical Center responded:
“No we’re a substance abuse treatment program, we treat all addictions and in fact
if patients have additional addictions we will discharge patients due to illicit
substance use: cocaine, benzos, ect. that has ongoing use that interferes
significantly with their health or treatment. We do include marijuana as well as
alcohol.” (Sheeran, 2014).

From a pharmacological perspective, methadone is only effective as a treatment for opioids.
Some clinics – typically those who ascribe to a harm reduction approach – are more tolerant of drug use,
believing that patients are still benefiting from their participation in the program.

11
12
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Here, the logic of recovery’s all-encompassing mandate, reflected through Sheeran’s use
of the term ‘substance abuse treatment program’ rather than ‘methadone maintenance treatment
program’ justifies the clinic’s intervention in a much wider range of behaviors. Pushing the
clinic’s jurisdictional boundaries even further, some treatment providers argued that their
mandate goes beyond drug use to include anything the counselor perceives to be unhealthy for
the patient:

“Yes we are an opioid treatment program but we’re here to address all of your
addiction[s] and I tell them ‘if your addicted to Pepsi and you’re a Diabetic and
it’s causing you health problems, we’re gonna be addressing your Pepsi use.”
(Bigitschke, 2014)

Treatment providers admitted that the changes have led to significant problems for some
long-term patients who resented the clinic’s new found concern with their use of alcohol,
marijuana, or other non-opioid drugs:
“We have patients that have been here since 1972, so there’s patients who’ve been
here [for] years, so they’re used to that older modality. And for many years, you
could be on a methadone program and as long as you weren’t using opiates, it
didn’t matter if you were using other substances. It was this frame of mind like
‘Oh, you’re using Cocaine, oh, your outpatient will deal with that. Or your using
alcohol, ‘well someone else will deal with that’. So it was pushed onto other
providers or it wasn’t the methadone maintenance programs problem. That’s no
longer acceptable. That’s no longer tolerated…. We have to address everything.
It’s not so much abstinence-only, it’s that all illicit substance use has to be
addressed. Meaning ‘Ok, it’s not just that you’re not using heroin, we’re going to
talk about your alcohol use, how you come in here everyday smelling of alcohol.
We’re gonna talk about how that impacts your health. So these patients who have
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been doing this for years are now like ‘What are you talking about?!’”
(Bigitschke, 2014).

The recovery model also involves the implementation of more contact between patients
and counselors. Whereas previous incarnations of MMT were characterized by clinicians as long
lines of patients, who would immediately leave after receiving their medication, the recovery
model required a great deal more:
“It’s no longer just coming in and getting your dose, your medication. They have
to do therapy, they have to do individual counseling, they have to go to group. So
there’s certain requirements that used to not exist and they’ve started implement
in the last 3 to 5 years. Back in the day, ten years ago, you would just go and get
your medication, sip, drink, maybe give a urine, and then you’ll have maybe a
monthly tox, a monthly session. And that was the norm. You saw the patient once
a month you know ‘You good? You ok? Everything good?’. Now the counselors
are expected to see the patients based on where they’re at. They come in and
during the first ninety days of treatment they’re expected to be seen weekly. They
are expected to go to group” (Bigitschke, 2014).

While treatment providers admitted that the change is experienced by many patients as a
negative, it also meant that many clinics were able to offer more services than had been
previously available. Although clinics varied in the services they provided beyond those
required by state and federal regulations - which generally relate to the number of required
counseling sessions – recovery-oriented grants have incentivized clinics to incorporate greater
amounts of services (SAMHSA, 2015; OASAS, 20152). Moreover, clinicians universally
described a cultural shift in substance use treatment services whereby the clinic was increasingly
seen as a hub for patients’ needs, often referred to as a “one-stop-shop.” Some of the larger
clinics incorporated a surprising amount of services including: medical care; cooking areas and
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equipment; laundry; television rooms and recreational space; as well as help with accessing
social services and links to numerous other agencies:
“[We’re] moving towards a more comprehensive model that incorporates lots of
different other things that people can be doing to help themselves, and to better
themselves, and to feel good about themselves, and lead healthier lives. There’s a
lot of conversation around wellness services. It could be nutrition, it could be
acupuncture, it could be yoga, meditation. And using, other than the typical
individual/group counseling services as a way of supporting peoples’ individual
recovery path.” (Greenfield, 2014)

“We have a wrap-around service that includes primary medical care in addition
to counseling, psychiatric, vocational, and nutritional. So we provide a large
number of services in the view that in order for recovery to occur you want to
affect as many life environments from health all the way to how people eat which
affects their health.” (Sheerin, 2014)

Although SAMHSA and OASAS administers characterized many of the additional
services as ‘tools in a toolkit’ rather than requirements, they are nevertheless becoming
institutionalized. While patients might not be punished for refusing to attend yoga lesions (yet),
they will be assessed for their willingness to participate in recovery-based activities, yoga being
one of them. Similarly, clinics will be assessed by SAMHSA and OASAS (in New York State)
regarding their implementation of recovery-based services. Thus, the focus on extra-abstinence
activities becomes increasingly normalized through subtle, innocuous, and nearly invisible
changes in policy that radically restructure the treatment model and patient experience.
Treatment providers admitted that many of the clinic changes are being driven by
changes in insurance. The increasing focus on addiction-as-disease, and recovery as its
treatment has enabled more people to access greater amounts of services. But it also contributes
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to the expanding jurisdiction and promotion of medical services. Clinic director, Carol Roberts
Matthews explains:
“When you talk about changes that will be occurring in these programs you have
to look at the information on insurance. The insurance is changing: managed
care, Medicade, it’s actually driving the changes. It’s not that we’re not gonna
provide services but it’s how we get paid for services, and so it’s gonna direct and
change how the clinics will be re-vamped and re-structured….. OASAS has new
instruments that we will be using.. We’ll be looking at the identifiers, the psychosocial needs of the patient, and sometimes, although we think they will fit the
needs of our program, this tool will say maybe [they] need a higher level of care
or a lower level of care, so they may not be able to get into our service and that
will be driven by, that’s where the managed care companies will come into play.”
The role of 12-step language and concepts
Treatment providers made significant use of 12-step language and concepts to justify the
recovery model’s more intrusive focus. Concepts such as the ‘dry drunk’ or ‘stinking thinking’
not only reflect the clinics’ power to interpret and categorize often highly subjective behaviors,
but also demonstrate the wide jurisdictional boundaries of the addiction-as-disease narrative.
The totalizing view of disease/recovery adopted here allows treatment providers power in areas
extending beyond those traditionally conceived of as “medical” and presume access not only to
behavioral issues, but to meta-physical aspects of their patients’ inner-lives.
“It’s not only being drug free. There is also behaviors and thoughts that have to
follow…. That’s where a lot of our patients get caught out. A lot of them will be
like (adopts mock whining tone) ‘Well I’ve been maintaining abstinence for six
months and I haven’t gotten a schedule reduction’. Well ok, yeah you’ve been
maintaining abstinence for six months but you’re not doing anything productive
in your free time. You still come in here with the same negative attitude. You’re
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still having problems with your counselor. You’re still keeping that ‘stinking
thinking’.” (Bigitschke, 2014).

As the quote demonstrates, the focus on extra-abstinence behavior within recovery is so
powerful that patients expecting privileges on the basis of abstinence alone are sometimes
positioned as ridiculous. Moreover, the discourse of recovery invoked here is based upon, and
actively constructs a particular view of ‘the addict’ as a wholly compromised person rather than
an individual seeking to reduce, eliminate, and/or manage some forms of drug use. The narrative
presents “addicts” as a monolithic category, and one that is wholly incapable of knowing what is
best for themselves, which justifies denying them agency over their treatment.
Conclusion

Government organizations who deal with substance use issues are re-framing treatment to
focus on recovery. The new paradigm is purposely open-ended to make recovery accessible to a
wide range of people, but is grounded in a disease model of addiction that includes aspects of the
neurological model as well as moral and spiritual conceptions of disease associated with 12-step
organizations. Government administrative organizations and local treatment providers (clinics)
see recovery as a means for bridging conceptual distinctions between substance use and mental
health disorders/treatment, and between different modalities for treating substance use disorders.
They are focused in particular on mainstreaming MMT (and other MATs to a lesser extent)
which they argue, have been ghettoized within the drug treatment community resulting in high
levels of stigma for patients, treatment provides, and the treatment in general. Although
administrators and clinic employees saw recovery as a more individualistic model, this applied
only in regards to making the treatment culturally sensitive and available to a diverse clientele
rather than allowing patients agency over their treatment.
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While all of the administrators and clinicians framed addiction as a disease or medical
problem, they used a combination of neurological and behavioral/spiritual models to describe it.
Most positioned medical approaches to drug use in contrast to moral and/or criminal ones, and
believed that the acceptance of addiction as a “medical problem” or “disease” would work to
remove stigma from people who use drugs. Treatment provider’s descriptions of addiction-asdisease, however, tended to focus primarily on behavior and meta-physical concepts like
spirituality. The construction of illegal drug use as addiction, and addiction-as-disease supported
the efforts of the clinic to promote recovery as the primary focus of MMT and treatment in
general. Medical conceptions of addiction and treatment also provided ideological support for
clinics’ intrusive and punitive practices complicating the commonly accepted view that medical
approaches to drug use are distinct from moral/punitive ones. Administrators at the clinic level
focused less on neurological conceptions and were more likely to describe addiction in
behavioral and spiritual terms.
Recovery was also seen by government agencies and treatment providers as a totalizing
process of self-reconstruction that went beyond the discontinuation of certain kinds of drugs.
Methadone clinics are increasingly seen as one-stop-shops where patients can access numerous
social services as well as information on nutrition, healthcare, and other services seen to be
important to recovery. Individuals on MMT are increasingly assessed according to standards
like community involvement, spirituality, and health generally, which were all understood
normatively. Similarly, concepts traditionally associated with 12-step groups are used more
frequently in reference to MMT. Thus, MMT under recovery is conceptualized as a program
designed to re-structure the entire person rather than a program to treat a particular category of
drug use behavior. Individuals who conceptualized their treatment in ways outside the recovery
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discourse tended to encounter problems with their clinic councilors sometimes leading to
punishment and/or dismissal.
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Chapter 4 Experiencing Recovery: The Decontextualized drug user

People on MMT (either currently or within the last two years) expressed a wide variety of
viewpoints regarding the role, and importance of recovery in MMT 13, yet nearly all of the
participants reported an increasing focus on recovery within their clinic. Specifically, they
described the increasing use of recovery language in their interactions with clinic counselors and
staff, and a growing pressure to conceptualize their own drug use through the disease model and
a desire for recovery. Many also reported that their clinic had implemented stricter rules
regarding illegal substance use and/or drinking alcohol, and become a more intrusive force in
their day-to-day lives.
Interviews with people on MMT also problematized the view of recovery as a flexible,
patient-centered model, capable of meeting the needs of a diverse population of drug users who
have very different drug use experiences, and who conceptualize their drug use and treatment
goals differently. Individuals with drug treatment goals that contrasted with the recovery model,
such as harm reduction, were seen by other patients as unready for treatment or as taking
advantage of the program and hurting those who were using it “correctly”. This is partly because
recovery is based on a decontextualized understanding of illegal drug use that ignores prohibition
and the War on Drugs as a driving force in drug users’ treatment decisions. Drug users regularly
involved themselves with MMT as a way of managing, or potentially escaping the day-to-day
difficulties of illegal drug use, and only adopted the language of recovery through exposure to
the recovery-based treatment culture. Similarly, participant responses suggested that the

This may be due, in part, to the high level of diversity among methadone clinics in the United States where the
multi-layered system of regulation – including federal, state, and local agencies – produces significant differences
in individual clinic policy and culture (SAMHSA, 2015)
13
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recovery discourse functions, in part, to obscure the role of structural factors in the problems
drug users’ experience, in favor of a view based on individual pathology.
Although all of the participants recognized, to some extent, the institutional push towards
a recovery-based culture, and the increasing use of addiction-as-disease narratives within MMT,
participants can be divided into three different subsets reflecting their responses to the emerging
recovery discourse. Participant responses did not always align perfectly with only one distinct
category, rather these are intended as ‘ideal types’ which represent the primary claims and
positions of each subset. Specifically, there were: 1. Supporters: participants who supported the
move towards recovery and lived according to its tenets; 2. Resistors: participants who directly
challenged the recovery model; and 3. Negotiators: participants who supported the shift towards
recovery but whose descriptions of how they used and benefited from MMT conflicted with a
recovery-based approach to substance use treatment.
1. Supporters: Supporting the move towards recovery and living by its tenets
Approximately one quarter of the participants on MMT both supported the move towards
recovery, and also reflected a recovery-based ideology in their personal accounts of drug use and
treatment. These were individuals who had discontinued both illegal substance use and drinking
alcohol, and who, in most cases, self-identified as being “in recovery”. Supporters who chose
not to self-identify as being “in recovery”, said that they were so removed from the world of
illegal drug use that it was no longer a part of their identity whatsoever, yet their behavior and
view of drug use aligned with those of the recovery model.
A hegemonic understanding
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Supporters adopted the hegemonic understanding of recovery as grounded in complete
abstinence from “drugs” and alcohol but also incorporating a focus on community, citizenship,
and spiritually – all understood normatively. This conception of recovery as a fundamental
change in personhood is reflective of the current recovery movement within substance use
treatment settings whereby individuals seek to re-make their entire lives in contrast to their
previous addict-selves (SAMHSA, 20153; MARS, 2016; Keane, 2002; White, 2007; White,
2000;). The following responses are typical of Supporters’ views on recovery as encompassing
more than the discontinuation of certain types of drug use:
“To me, it’s [recovery] not just not using drugs, it’s changing my attitude,
behaviors, who I hang out with, the way I present myself, the way I live everyday.
Cause now I try to help people. I try to do what people did for me when I was
struggling, and that helps me stay clean.” (John, 2016)

David: How do you define ‘recovery’?
Gene: I define it [recovery] as working, living life in society, raising a family if
that’s the case and being part of society.
David: Would abstinence be required to be in recovery?
Gene: yeah, absolutely.
Although recovery is presented here as an uncomplicated (and even objective) diagnostic
entity, its reliance on normativity problematizes that view. Since the definition of recovery
includes things like work, school, and being perceived as a good citizen, it obscures the
hierarchical nature of our society where access to monetary and other forms of capital are
dispersed unevenly and often along racial and class lines. For example, since African Americans
and Latinos are less likely than whites to be employed (US Dept. of Labor, 2016), they will be
similarly disadvantaged in regards to assessments of recovery. Thus social and cultural
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inequalities become embedded within the seemingly objective term, giving it the power to
discriminate without appearing to do so. Scholars have argued that in the post-civil-rights era,
racism functions most often through ostensibly race-neutral language and policies like these
(Doane & Bonilla-Silva, 2003; Bonilla-Silva, 2001) and Reinarman and Levine make a similar
claim in regards to racialized sentencing policies that distinguish between crack and powdered
forms of cocaine (1997).
Recovery also institutionalizes normative ideas about how to live properly, such as
community participation and spirituality, which are far from universal. By linking addiction to
such vague and subjective markers as choice of friends, the importance (or meaning) of altruism,
and/or maintaining the “right attitude”, recovery becomes a powerful tool for the enforcement of
norms. Moreover, since it is based on a totalizing conception of wellness with a limitless
jurisdiction in regards to re-making the self, recovery-based discourses could easily be applied to
any number of personal lifestyle choices including: choice of romantic partner, membership in
particular organizations, or voting.
Science and the disease model
Supporters also conceptualized their drug use through the lens of the disease model.
Moreover their accounts of addiction were similar to those of treatment administration
organizations like Substance Abuse and Mental Health Services Administration (SAMHSA) and
New York state’s Office of Alcoholism and Substance Abuse Services (OASAS), who rely upon
an intentionally flexible conception of addiction based in the medical model but incorporating
biological, spiritual, and community-based components. Thus, participants from this subset
utilized various combinations of addiction-as-disease theories to understand their drug use and its
treatment. For example, in the following interview portions, Nadine stresses the genetic
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component of addiction and feels strongly that it is a disease, while Marshall, who prefers the
term “illness” sees addiction more in terms of actual damage to his brain through early childhood
drug use.
David: When you think about addiction, do you think of it as a disease?
Nadine: Yes! Yes, it is a disease! It is. It is a disease.
David: Ok, tell me more.
Nadine: It’s a disease because, like I said, my father was an alcoholic. And I think
it’s because different people, like their mother or father, or somebody in their
family has had this disease before. And that’s why I feel that it’s a disease.
David: Because of genetics?
Nadine: Yes, genetics. It could be to alcohol or pills or whatever.
“I don’t know if ‘disease’ is the right term but I think of it as an illness. I think my
brain forever changed, since I started early, when I was a kid…. I feel like I’m
forever damaged in some way.” (Marshall, 2014)
Part of Supporters addiction-as-disease narrative involved establishing conceptual
distinctions between heroin and methadone. Although they are pharmacologically similar – a
quality that enables methadone’s use in MMT – Supporters positioned methadone as a
“medicine”, discursively the opposite of heroin, the “drug” that it treats. When describing how
MMT worked, most avoided narratives that stressed methadone’s role as a substation
medication, i.e. one whose efficacy is based on its similarity to heroin and other illegal opiates,
and instead used discourses that positioned methadone as an active medicinal agent, working to
repair the harm caused by heroin (and/or other illegal opioids). As Chad, a patient who also
organizes for recovery-based advocacy groups confidently stated: “Methadone actually allows an
endogenous system in the brain, a natural system, to heal.” (Chad, 2014)
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Like clinic and government administrators, Supporters also used notions of science as a
means of legitimizing the disease model and marginalizing those who hold opposing viewpoints.
Despite the high level of disagreement among scholars on any unifying of theory of addiction, as
well as numerous critiques of the disease model (see for example Keane, 2002; Buchman, 2010;
Reinarman, 2005; Courtwright, 2010), science was presented as a monolithic entity with uniform
views that were seen as ‘truth’ by definition. When I asked Chad about criticism of the disease
model, or other ways of understanding drug use, he answered:
“Every credible academic, medical, and research organization in the world does
agree [that addiction is a disease]. What I say to them is: there is no ‘disease
model’, there is no ‘disease theory’. If we are people that believe in science, it’s a
fact.” (Chad, 2014)
Power dynamic and reduced agency
Such responses, however, must be understood contextually within the coercive power
dynamic between patient and treatment provider. As Goffman and others have pointed out,
institutions exert ideological pressure upon their charges to accept the dominant narrative (1963;
Foucault 1988). Reinarman focuses specifically on this “pedagogical process, in which addictsto-be learn the lexicon of disease/recovery from counselors, therapists, judges, probation and
parole officers, treatment providers, and other addicts” in his analysis of how the disease model
is produced by specific actors and institutions (Reinarman, 2005: 315). This is particularly the
case for populations like “addicts” or people diagnosed with a mental illness since they have a
reduced level of agency in regards to avoiding said institutions. For example, some people must
attend methadone maintenance clinics by court order and face potential jail time for noncompliance (Brecht, Anglin & Wang, 1993) and even those who attend MMT ‘voluntarily’ are
operating within the context of criminalization which complicates notions of volition in regards
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to choosing to attend (or not attend) substance use treatment. Thus participant responses,
particularly when they align so closely with the dominant institutional narrative, may be read as
evidencing the internalization of the disease model, as much as a patient’s actual views on the
phenomenon – indeed, the context of constrained agency for illegal drug users blurs the line
between the two.
Othering
Individuals from this subset also saw the tenets of the recovery model as a hierarchical
means of determining which patients were “there for the right reasons” and others, who needed
to be purged from treatment. They were very against the notion that MMT could or should be
used as a way of reducing harms in the lives of active drug users, and felt that anyone not
pursuing abstinence-based recovery had no place in the program. For example, the following
responses are representative of Supporters’ views on patients using MMT for pragmatic or harm
reduction reasons.
“If you’re trying to use [illegal drugs] and be on MMT, you’re only fooling
yourself and eventually you’re gonna get caught anyway…. And that [using
heroin while on mmt] defeats the purpose. It defeats the purpose, if you’re on
methadone, why do you need to use heroin. It doesn’t make sense. To me it
doesn’t……It’s a privilege to be in maintenance. It should be a privilege that you
earn. It’s only right that they do that [kick people off for using drugs]” (Nadine,
2014)
“Listen, everybody screws up, everybody slips, I’m not saying that [they should
be kicked off the program for that]. But if that’s the reason they’re getting on [to
reduce the harms of drug use rather than pursue abstinence-based recovery] then
‘no’” (Francine, 2014)
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Thus, those in support of recovery reflected the institutional viewpoint that individuals
utilizing MMT for pragmatic reasons, or as a form of harm reduction, were either not ready for
treatment or that they were trying to cheat the system. Koester, Anderson & Hoffer reject this
interpretation in their qualitative study of what motivates heroin users to enter MMT (1999).
The authors found that in contrast to the all-or-nothing view advocated by the recovery model,
heroin users often engage with MMT to manage rather than discontinue their drug use. They
characterize MMT as a pragmatic strategy utilized in multiple ways by a highly criminalized
population with very limited options. The authors point out that “before discounting the
methadone treatment attempts of street users who continue to use illicit drugs as illustrations of
their manipulative behavior or ‘lack of readiness’ for treatment, we consider both the immediate
benefits of these treatment interludes in reducing other risks associated with the addict lifestyle,
in temporarily improving an addict’s quality of life, and possibly acting as pilot tests for an
addict’s eventual long-term commitment to treatment.” (p. 2151). They argue that we should
consider “drug users’ own models of drug use and treatment” and that “these addict-led
adaptations of methadone maintenance treatment may encourage us to rethink what we mean by
‘successful’ treatment” (p. 2151).
Interestingly, despite their support of the disease model, most advocated punishing
individuals for drug use, problematizing the claim that medical and punitive models are
disparate, and dichotomous approaches to drug treatment. Although those in support of the
recovery model consistently positioned MMT as a form of healthcare, it was described as a
particularly punitive one that must be earned by accepting the dominant narrative and behaving
as proscribed, or else. This aligns with Rebecca Tiger’s analysis of Drug Courts, another form of
drug treatment ostensibly based on a medical model, but whose actual approach combines a
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complicated alchemy of medical and punitive approaches to controlling the behavior of drug
users (Tiger, 2012). Similarly, by describing MMT as a “privilege that must be earned”
Supporters framed it as a benevolent and paternalistic intervention that drug users should be
thankful for rather than critical of. This framing of the program positions any critique of the
system as a selfish attempt to bite the hand that feeds.
Moreover, because participants from this subset see individuals using MMT for harm
reduction as giving a bad name to “legitimate” patients, they often advocate reporting them to
clinic staff. This not only results in the marginalization and dismissal of numerous patients who
benefit from MMT, but has also contributed to a combative environment at clinics as well as on
MMT-based web forums where such issues are sometimes discussed.
2. Resistors: Directly challenging recovery
Other participants, particularly those with greater exposure to harm reduction and/or drug
user rights activism, directly challenged the recovery discourse. These participants, who also
accounted for approximately one quarter of the MMT patients, were particularly critical of the
disease model of addiction. They challenged addiction-as-disease narratives in a number of
ways, but most often by arguing that drug use is a highly diverse activity and that outcomes are
influenced by a multitude of variables. Resistors relied upon their own experiences with drug
use and treatment to illustrate the reductive quality of addiction-as-disease narratives, pointing
out how the difficulties they encountered as a heroin or prescription opioid user (and
consequently, what MMT alleviated) often involved problems associated with prohibition such
as the scarcity/high price of illegal drugs and/or the threat of violence and arrest rather than just
the pharmacological effects of using opioids. Thus, many saw MMT not as a medicine used to
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treat the disease of addiction, but as a pragmatic means of avoiding or minimizing the harms of
illegal opioid use:
“[As a heroin user, you] Gotta hustle to get that money and I wasn’t taking care of
my girl or me, and it’s just rough. It was rough…. [I got on MMT to] stop that
hustling, that was the main reason. That everyday, three times and four times,
trying [to get] money to supply me and my girl, it was too much. Too much.”
(Grace, 2016)
“I think it’s [heroin] the healthiest drug you can possibly take. The drawbacks are
the cost and the system you have to go through to get it. It’s all the imposed
stigma that creates the detrimental aspects.” (Pauline, 2014)
Others criticized the disease model by arguing that while everyone experiences problems
and difficulties, drug users’ problems are artificially constructed as evidence of a particular
theory of addiction. As one participant responded when asked about recovery.
“I have never considered myself in recovery because I don’t believe that anybody
is perfect. I’ve lived with a lot of different people, whether they’re roommates,
mother or father, brother, and they’ve all had their own problems. Some of them
have been [with] substances, and some have been, in my opinion, worse than
that.” (Barry, 2014)
Harm reduction vs. recovery
Resistors often positioned recovery and harm reduction as oppositional ideologies within
substance use treatment. This was most often the case when participants had been exposed to, or
were personally involved with, harm reduction politics. For example, Pauline, who has a long
history of involvement with the harm reduction movement used that experience to reject the
identity of ‘addict-in-recovery’. Although she has been abstinent from illegal drugs for many
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years, when asked if she defined herself as being in recovery, Pauline differed, emphatically
declaring herself a “total harm reductionist”:
“Never, never, because I was not sick. I was using responsibly. I never missed
work, I never was irresponsible, I always paid my bills, I took care of shit and I
was not sick and I didn’t need to recover. I’m a total harm reductionist……..I
don’t believe in it [The disease model of addiction]. I believe it’s [drug use] a
choice. I believe it’s a totally reasonable choice, it can be a responsible choice. I
do recognize that there are people who don’t use drugs responsibly, there’s people
who I believe can’t use casually, just like with alcoholics…. But that said, I think
for most people, it’s a choice. It can be a responsible choice, and one that
enhances your life and your abilities.” (Pauline, 2014).

Pauline’s focus on harm reduction as a means to reject the recovery label and its
association with the disease model of addiction is interesting since harm reduction is, in many
ways, a medicalized response to drug use (and other behaviors seen as involving risk). However,
her response illustrates the strong current of resistance in harm reduction to any universal theory
of addiction, particularly one based on individual pathology. While there are undoubtedly
disease model advocates who value harm reductions’ less punitive approach (for articles on
attempts to merge the two approaches see: Futterman, Lorente & Silverman, 2004; Marlatt,
Blume & Parks, 2001; and Kellogg, 2003), most harm reductionists are interested in shifting the
addiction (or drug use problems) discourse away from looking at ‘individuals with a disease’,
and towards one that supports the “rights of people who use drugs” (Harm Reduction Coalition,
2016). Thus, many harm reductionists resist the increasing use of medical rhetoric to address the
etiology of drug users’ problems and focus instead on criminalization and the War on Drugs.
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However, her use of normative and subjective markers of success, like paying bills and
not missing work, to argue that she is not an addict complicates the narrative. Whereas harm
reduction has traditionally avoided the use of such categories as a proxy for addiction, preferring
instead to “meet the client where they’re at”, the recovery paradigm has embraced them. Thus
while Pauline declares herself a harm reductionist (and much of her narrative reads as such), it is
also imbued with recovery-oriented values. This can potentially be read as mirroring harm
reduction’s recent history of colonization by comparatively normative and mainstream views of
drug use. As discussed in Chapter X, activists often argue that the more radical, core beliefs and
grass-roots philosophy of the movement have been diluted as harm reduction becomes a more
mainstream part of modern medical practice. In this context, Pauline’s response suggests the
proliferation of recovery narratives, even onto the terrain of seemingly oppositional philosophies
like harm reduction.
Similarly, despite Resistors institutional critique of recovery and the disease model, some
framed their relationship to the clinic using familiar tropes of addiction that position the drug
user both as the architect of her own problems, and as someone who deserves to be treated
poorly (until earning the trust of the clinic/society). For example, when I asked Grace, who still
uses drugs, believes they should be legalized, and does not identify as being in recovery, how
MMT could work better for her, she initially replied “I would want less days [to have to go in to
the clinic], cause I have to go 6 days a week.” Like most people on MMT that use illegal drugs,
Grace is not given takehome doses (with the exception of Sunday when the clinic is closed) and
must commute to the clinic every day. Although this practice is often criticized as an overly
punitive, impractical, and unnecessary obstacle in the way of treatment for an already
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marginalized and treatment-averse population, Grace believes that “it’s my obligation to get my
act together and stop giving dirty urines.” (Grace, 2016)
Criticism of the disease/recovery model, however, was not limited to individuals
involved with the harm reduction movement who might be expected to reject the paradigm.
Others argued that the dichotomy established by the model, between recovery and active
addiction, was both pejorative and overly-simplistic, and was therefore unable to account for the
myriad ways that people interact with drugs. Participants also criticized the biological
determinism of the disease model using discourses of personal responsibility and by rejecting the
assertion that drug users are devoid of agency in regards to their drug use decisions:
“I don’t feel comfortable with everything that goes with that title [the disease
model of addiction]….. My hand never shot me up against my will” (Melissa,
2014)
“I really don’t [think it’s a disease]. I remember being in rehab when they said
‘Oh they found out it’s a disease, that there’s this chemical THIQ’ and I’m like
‘what the fuck ever man’, I said ‘I don’t really think so’. Cause you know, really
addiction – sex addiction, food addiction, this and that, money, power, fame - I
said ‘come on’, you know. I guess for me, it’s like a scapegoat, like giving up a
little responsibility. To me personally, I don’t consider it a disease, I guess it’s
behavioral.” (Dale, 2014)
MMT for active users
In contrast to the recovery model, which posits abstinence as the central goal (or at least
the preferred outcome) of treatment, participants from this subset often stressed the benefits of
MMT for active drug users. This was firstly evident through their accounts of what initially
motivated them to try MMT. Although everyone was asked about the circumstances that led
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them to pursue treatment, very few mentioned a desire for abstinence or recovery, and none used
medicalized or disease language. Instead, participants focused on MMT’s ability to stabilize
their lives by reducing/eliminating the need to participate in dangerous, time consuming, and
illegal activities. Some wanted to use less opioids or to discontinue opioid use entirely while still
using other drugs, while many were unsure of their drug consumption goals and simply wanted
to escape the world of criminalized drug use. For example, Barry, who initially tried MMT after
the fatal overdose of a close friend, explicitly states that abstinence was not his goal upon
entering treatment but instead describes MMT as a strategy for minimizing the day-to-day
dangers and difficulties involved with dependence on an illegal substance:
“I was tired of waking up and feeling like shit every morning and driving to the
West side and picking up dope. I actually wasn’t that tired of it to be honest with
you, but I figured there was a better way, something else to make me feel normal,
because I didn’t feel normal otherwise……I didn’t want abstinence from all illicit
drugs by any means. I definitely wanted to stop the lifestyle that I was going to go
back down.” (Barry, 2014)
“I don’t think that the methadone community has the idea that abstinence as being
the total goal of recovery for MAT. [It’s] to get your life together. I mean you
can’t be fucking going to the West side, shooting dope, shooting dope in the
bathroom at work, you’ve got to get high every six to eight hours. There’s no way
to live a life like that.” (Barry, 2014)
Barry, who occasionally used illegal opiates and crack cocaine, as well as smoking
marijuana and drinking regularly had few, if any problems at his initial, harm reduction-based
clinic. Methadone allowed him to avoid the hazardous daily commutes to buy heroin and to
minimize the concomitant dangers involved with illegal drug use. He maintained a job, took
classes, and described his life as the most stable it had been since he began using heroin.
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However, after moving to Massachusetts, he found the clinics to be much stricter, and quickly
ran into difficulties with his counselor, particularly over the clinic’s use of breathalyzers to test
for alcohol use. He argued:
“I was able to do the things that normal people do [at my old clinic]. Normal
people go to bars… Normal people smoke weed. Normal people do those things
when they want to do them. Now if you’re gonna tell me because when I was
between the age of 16 and 22, I shot dope and I was a heroin addict, fine, you can
say that, but don’t let that define the rest of my life. Don’t tell me I can’t go to a
pub and have some beers. Don’t tell me I can’t smoke a joint with my buddies,
cause that is bullshit….. You just want to live a regular life and they try to impede
on you living a regular life, then that’s where it bothers me, and that’s where I say
‘you know what, fuck it’ and that’s why I said fuck it in Massachusetts.” (Barry,
2014).
After numerous problems with his clinic, Barry eventually decided to leave treatment and
unfortunately died shortly thereafter of an opioid-involved overdose. Research on leaving MMT
(either voluntarily or through an administrative detox 14) demonstrates that Barry’s experience is
not unique. Individuals’ evidence increased rates of substance use, as well as numerous related
negative health outcomes including overdose and death upon leaving treatment (Cousins et al.,
2011; Magura & Rosenblum, 2001; Farrell et al. 1994).
Other participants reported health risks like skin abscesses, transmission of blood-borne
diseases, and the fear of overdose as reasons for trying MMT. One began treatment after finding
out she was pregnant and knowing that withdrawal during the course of her pregnancy - a near

An Administrative Detox in a punitive measure, enacted by the clinic, whereby the patient’s dose is
systematically reduced to zero at which point the patient is discharged (they are used both as a response to rule
breaking and for failure to pay clinic fees). Administrative detoxes are often carried out much more quickly than is
medically recommended, and certainly too quickly for the patient to be beyond withdrawal upon the cessation of
methadone. Thus, patients are generally terrified of being Administratively detoxed.
14
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certainty if she remained using only illegally obtained opioids - could jeopardize the health of
her unborn baby. Harm reduction projects like syringe exchange programs (SEPs) and safe
injection facilities (SIFs) have demonstrated that indirect health risks like these are more
associated with criminalized drug use than drug use itself (Hagan et al., 1995; Lurie, 1993;
Moses, Vlahov & Normand, 1995) and studies have found that MMT is the most effective means
of avoiding them (Ball & Ross, 2012; Farrell et al., 1994; Joseph, Stancliff & Langrod, 1999).
Thus, Resistors often described MMT as a means of avoiding harms contextually associated with
drug use under criminalization rather than on avoiding drug use itself.
Withdrawal
Resistors also focused on how MMT allows them to avoid withdrawal. Withdrawal was
seen as problematic not only because of its unpleasant effects, but because of the inability to
work, stay in school, or pursue non-drug related activities when periodic sickness was a regular
occurrence. Participants provided numerous accounts of their experiences before MMT (or
during periods when they were not involved with the program), of waking up in the morning,
already in withdrawal after being unable to procure opiates the night before, and then losing a
job, either from calling in sick, or going to work and preforming poorly. Resistors who
continued to use substances often conceptualized MMT as a backup or a safety net, for periods
when they were unable to obtain their drug of choice. Thus, opioid-dependent individuals were
able to participate in normal life activities like work and school that were impossible to maintain
while relying strictly on the illegal market.
Similarly, participants reported a strong connection between withdrawal and their
willingness pursue risky activities such as syringe sharing or buying from an unknown source.
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One individual stated only half-humorously, “I don’t share needles ever. But if you catch me
dopesick enough, I’ll shoot up with anything” (Guy, 2014).
Studies have documented how drug users in withdrawal are more likely to engage in
risky practices (Hughes, 2004; Connors, 1994; Ross et al., 1994), and that MMT is one of many
“indigenous strategies and tactics” used to manage their consumption and avoid risky behavior
(Mateu-Gelabert, 2010). Thus, participants used MMT strategically, either as a safety net during
periods of particular difficulty, or as a long-term plan to avoid withdrawal entirely. This allowed
them to maintain employment or enroll in school without the pressures of having to obtain an
illegal substance multiple times each day, and without the constant threat of withdrawal. Yet, as
the following interview portion demonstrates, such behavior is usually seen as negative by the
clinic regardless of how the patient conceptualizes their treatment:
“It [my reason for getting on MMT] was basically to have a way to not be sick
and function better without having to take dope. But then what it turned into, I
started taking dope on top of that, and it became a get out of jail free card, where I
could use on top of it [methadone], and the methadone kept me from being sick.
They made it sound like a negative thing cause their goal is for you to be
completely abstinent.” (Vic, 2014)
Clinics’ role in policing non-opioid drug use
Not surprisingly, participants from this subset did not believe that clinics should be
policing their patients’ non-opioid drug use, and argued that their increasing concern was
irrelevant, counter-productive, and dangerous. They pointed out that such policies discourage
people from signing up for treatment and also marginalize, and/or push many individuals who
benefit from MMT out of the program. Many had stories of friends or family experiencing
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conflict at their clinic that were uncannily similar to Barry’s. When asked about the clinics’
increasing involvement with patients’ non-opioid drug use, Resistors argued:
“You’re going to the clinic for treatment for opiate addiction. That’s what
methadone’s for. It’s not a treatment for cocaine addiction, it’s not a treatment for
alcohol addiction.” (Karen, 2014)
“In my opinion using other drugs is a whole different topic. I was trying to get off
my heroin habit, that’s all I saw methadone as useful for. (Pauline, 2014)
Even some of the participants who believed in recovery were critical of clinics’
increasing concern with their patients’ non-opioid drug use. Although these participants
believed that everyone should be encouraged to pursue abstinence-based recovery, they pointed
out that non-compliant patients are still better off on MMT than off of it. For example, Gene,
who had been in various MMT programs for more than 40 years contrasted the new recovery
approach with the views of Drs. Dole and Nyswander, the highly respected physicians who
began the first experiments with MMT:
“The people that started the program, Dole and Nyswander, they looked at the
program as harm reduction… They also accepted certain behaviors, smoking pot,
even not being employed, as long as there wasn’t really criminal activity and they
looked at it as harm reduction. The other people that came into the system later
on, they’re much different. They didn’t believe in harm reduction to a degree…
When I left the system, the whole thing was treatment plans, monthly notes,
etc…. They never tested years ago for marijuana use. Then all of the sudden they
started testing for it, and putting increases into people’s schedules, and stuff like
that. [This started] about ten, twelve years ago.” (Gene, 2014)
A review of Dole and Nyswanders’ publications at least partially supports Gene’s claim.
Firstly, Dole and Nyswander did not remove participants from early clinical trials for illegal drug
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use, and even saw their “experiments in drug usage” as potentially beneficial since methadone
“blocks” the euphoric effects of short acting opiates 15, and drug users were unlikely to continue
using illegal opiates after spending money without result (Dole & Nyswander, 1965). More
importantly, although Dole and Nyswander were clearly working within a medical model (and
before the thrust of the harm reduction movement), their language suggests that much of MMT’s
power resides in its ability to decriminalize, writing that “Methadone maintenance makes
possible a first step toward social rehabilitation by stabilizing the pharmacological condition of
addicts who have been living as criminals on the fringe of society” (Dole & Nyswander, 1976:
2117). Moreover, in their ten-year review of MMT, they argue against excessive rules and
regulations which they cite as the most common reason for addicts (sic) to reject treatment, and
chastise the public at large for their morally-based lack of enthusiasm for substitution treatment,
pointing out that “What was not anticipated at the onset was the nearly universal reaction against
the concept of substituting one drug for another, even when the second drug enabled the addict to
function normally” (2117).
Resisting recovery
Because of their deviant views, participants from this subset often maintained a strategic
approach when dealing with clinic staff. Although the extent of effort required to stay out of

The ability of methadone to “block” the effects of other opioids is potentially a misnomer. While using
methadone certainly makes it more difficult to obtain the euphoric effects of other opioids, this is usually
conceptualized (by drug users) as a function of methadone’s potency and its related effects on patient tolerance.
Thus, people on standard doses of methadone are unlikely to feel other opiates because methadone is more
potent than other competing opiates - it would probably be more accurate to say that methadone ‘trumps’ the
euphoric effects of other opiates. Since methadone is significantly less euphoric (though not devoid of euphoria)
than short-acting opiates like heroin, the euphoric results of taking short-acting opiates while maintained on
methadone are usually negligible. However, with a comparatively low dose of methadone, it is possible to achieve
euphoric effects from short-acting opioids and some patients specifically seek out this balance. For more
information of how methadone is constructed in regards to pleasure see Houborg, 2012.
15
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trouble varied tremendously based on the clinic’s philosophy, Resistors tried to minimize any
chance of conflict by appearing to be ‘going along with the program’ and telling staff ‘what they
want to hear’. For some, this simply meant discussing their treatment goals using the language
of disease and recovery. However, others had to engage in more serious forms of trickery to
avoid increased surveillance and discipline at their clinics. For example, while all clinics require
monthly drug screens from patients, some conduct the test via a urine sample provided while a
staff member looks on. Not only was this controversial practice cited by patients as a stressful,
humiliating, and unduly invasive experience, it also posed practical problems for individuals who
continued to use illegal drugs. Since a ‘dirty urine’ usually results in the loss of take-homes
(meaning that individual would have to attend the clinic every day) and could lead to an
administrative discharge, they significantly affect the quality of life for MMT patients.
Consequently, participants reported knowing patients (who used illegal substances) who
regularly bought black-market “clean” urine from compliant patients whose urine would show
the presence of methadone, but nothing else - some even used prosthetic genetalia, modified to
give the appearance of urination.
3. Negotiators: Participants supporting recovery but whose treatment accounts
problematize recovery-based treatment
The third subset of patients however, were not only the most numerous – approximately
half of the MMT patient group - but most reflected the tensions inherent in the recovery model.
Although Negotiators rhetorically touted the tenets of recovery, such as the disease model of
addiction, the need for a complete personal transformation, and the belief that abstinence was the
true purpose of MMT, a critical analysis of how they used, and benefited from the program often
conflicted with recovery’s one-size-fits-all approach.
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Norms, Social Construction, and othering
Although Negotiators believed in recovery and most rejected the idea that MMT could or
should be used as a form of harm reduction, their views concerning what constituted acceptable
behavior were often shaped by their norms, values, and socially constructed worldview. This
was apparent first through the difficult-to-pin-down meaning of the term “drug”, a concept
implicated in nearly all of addiction and recovery discourse. The subjective and culturally
determined nature of “drugs” as a category ultimately leaves questions as to what counts as
“recovery” up to endless debate, and usually determined by individual and group norms. Thus,
participants who occasionally drank alcohol tended to view that as within the bounds of recovery
but rejected recreational marijuana use. Others smoked marijuana and argued for its
acceptability while dismissing the claims of those who drink. Since the recovery discourse is
involved in expanding the conceptual boundaries of addiction-causing substances and behaviors,
one can imagine how debates over substances like cigarettes, chewing gum and sugar, or
behaviors such as playing the lottery can further complicate the already tenuous boundaries
between recovery and active addiction.
Normative views were, as always, affected by racial, class, and age-based variables that
often took the form of othering. The following interview with Francine, a long-time MMT
patient in recovery, demonstrates not only how the ostensibly objective standards of recovery can
be adapted to normative ideas about deviance, but also how such an approach obscures structural
hierarchies and cultural differences. Initially Francine expresses a hard-line, abstinence-only
approach to individuals using MMT for harm reduction purposes, stating:
“I think that’s [using methadone to moderate drug use or for otherwise nonabstinence reasons] absolutely ridiculous and it pisses me off when I see people
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that are doing that. Because it gives us such a bad name. Cause it [MMT] does
work and you get these assholes who are still getting high… It pisses me off
because you have these people who would get on it because they figure well they
can’t afford to get high anymore so they get on ‘meth’, and they’re not doing it
for the reason of they want to clean up their lives and that really irritates me…
Why be on it? Why do that? You have such a chance of getting yourself together.
Why are you gonna take it and then still go and screw around? It just makes no
sense to me.” (Francine, 2014)
However, when asked to clarify which substances constitute grounds for punishment, it
becomes clear that her conception of recovery is molded not only around class-based cultural
norms that differentiate between acceptable and non-acceptable forms of drinking, but also by
her own preferred drinking behavior:
David: So when you say that people should have to be abstinent in order to be on
the clinic, would that include things like alcohol and marijuana?
Francine: Absolutely, absolutely. You know, I never had a problem with alcohol.
Do I drink? I have a drink, but you know, I don’t really drink socially. It would
just be like at a wedding.
David: Ok, so it wouldn’t apply to drinking alcohol?
Francine: But not drinking just to drink, you understand what I’m saying. Like if I
went out to dinner for my parents or something and we all had a bottle, or a glass
a wine [that would be ok]. But as far as drinking, to sit at home and have a drink,
no I don’t think that’s necessary.
Firstly, Francine’s views on acceptable forms of drinking are clearly based on her own
preferences. Moreover, her descriptions are highlighted by references to wine and going out to
dinner, both forms of drinking associated with higher socio-economic status groups. Yet
drinking at home, a far more affordable form of drinking culturally linked to working class
imagery is constructed by Francine as problematic and outside the bounds of recovery. It is not
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difficult to imagine how the symbolic markers associated with different substances (for example,
blunts, Champaign, malt liquor etc.) could affect its position in regards to recovery, and in this
way, racial and class-based hierarchies are simultaneously built into, and obscured by, the
seemingly objective narrative of recovery.
The etiology of drug use problems and the purpose of MMT
When asked, participants from this subset dutifully referenced the disease model to
explain their drug use problems. However, a more detailed account of their drug use and
treatment histories suggested structural and legal factors as causing the majority of the
difficulties they experienced while using drugs. Like the Resistors, many in this group reported
problems associated with safe and reliable access to drugs and consequently, withdrawal, as a
primary motivation for initiating MMT. For example, although the following responses are from
participants who reported seeing addiction as a disease and believe that recovery is the true
purpose of MMT, their accounts of the circumstances that drove them to MMT focus entirely on
the practical and structural-legal difficulties of obtaining illegal drugs under prohibition rather
than a medical or health related inability to ‘just say no’ to “drugs”:
“[I got on MMT] because I was waking up sick too much and, you know, have to
steal to support my habit. You know, we have to do things to support our habit.”
(Spencer, 2016)
“The dope was the worst because if you don’t have it, you get sick – that was the
purpose of the methadone. That was the purpose of the methadone…. In other
words, if I couldn’t get that [heroin], the meth[adone] was a total backup”
(Donald, 2016)
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“I can just do this [take methadone] and I won’t have to worry about
anything…The illegality and the cost and then dealing with knuckleheads in the
street that try to rip you off. It was just easier and it was stable too.” (Tom, 2014).
Despite Negotiators reliance on the disease model, it seems ill-suited to describe their
actual experiences as drug users and MMT patients. Their accounts directly reference heroin’s
status as an illegal drug as well as the dangers associated with the black-market as downsides to
heroin use that motivated them to try MMT. Similarly, they identify the added ease and stability
of MMT as compared to the hustle of illegal drug use. Thus, Negotiators’ accounts suggest that
MMT allows opioid-dependent individuals to access opioids without the dangers and hassles
imposed by criminalization – this mirrors my own experience with MMT.
Other Negotiators painted similar pictures of MMT. For example, Sofia, who
conceptualizes her drug use through the disease model and still occasionally uses drugs but is
working towards recovery, reported that “It was hard to get the money to get heroin
everyday…….When I didn’t get the money, I was getting sick” (2016). She has currently been
on MMT for 13 years, and although she uses marijuana, alcohol, and occasionally crack cocaine
and heroin, MMT works for her “because I didn’t have to worry about getting sick or nothing. I
could just go to the methadone clinic, drink [my dose of methadone] everyday, and not have to
worry about withdrawal or nothing like that.” (Sofia, 2016). When I asked if she was more
concerned with being abstinent or stable, she immediately responded that stability was her
primary concern, adding that “It worked out great for me. At the time [before getting on MMT] I
didn’t have no place to stay. Once I got on the methadone program everything started to fall into
place” (Sofia, 2016). Although Sofia views her experience with MMT as being very successful
and stresses that it has improved her life tremendously, her clinic counselor regularly pressures
her to abandon all substance use – a position that Sofia frames as “trying to tell me the right
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things”. Similarly, she views the increasing use of surveillance and punishment by the clinic as
“concern [for her]”, despite the fact that it has direct effects on her ability to access takehomes
(she currently gets none) and could eventually result in her being Administratively Discharged.
The following interview also challenges the recovery model’s attempts to frame MMT
patients’ success as the result of switching from a “drug” to a “medication”. Casey, a patient in
long-term recovery who is completely abstinent from drugs and alcohol also described her
addiction through the language of the disease model. However, she focuses on the similarities
rather than the differences between heroin and methadone, eventually experiencing a conceptual
‘lightbulb moment’ regarding their relative potential as treatment substances:
Casey: I think I was born with it [addiction]. I have a very low pain tolerance,
both physically and mentally. I think there’s something missing from my
endorphins to begin with, and then I think through the use of narcotics, I
destroyed my receptors.
David: So do you characterize it as a disease?
Casey: I do, oh yeah. I think that this was something I was born with and then
through environmental traumas and use [it was made worse]…. Methadone just
took care of all that. It just took away the crave. It helps me tolerate pain both
emotionally, mentally, physically.
David: Did heroin do that for you too?
Casey: Oh yes! Day one, day one! I would tell you that heroin, in some ways, I
know this is gonna sound weird, but it saved my life.
David: That doesn’t sound weird at all.
Casey: Well, you know, some people would say…. my parents would tell you that
it destroyed my life but I’d tell you that I probably would have suicided if I hadn’t
found something.
David: So both heroin and methadone had that same effect of treating the mental
and physical anguishes, but heroin was probably tougher to maintain.
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Casey: Yeah, you can’t maintain it. You can’t lead a healthy lifestyle. You know,
I bet if I could get heroin from a medical doctor I think one or the other would
work just as well. I’m convinced.
Like the responses above, Casey locates the difficulties of opioid use not in their
pharmacology - in fact she states that opiates have always helped her to the point of saving her
life – but in their structural position as an illegal drug and the lifestyle that illegality engenders.
In contrast to the Supporters attempts to discursively separate the two substances, Casey’s
account suggests that MMT’s ability to improve lives is not related to methadone’s
‘medicineness’ as compared to heroin’s ‘drugness’, but because of the quasi-legal environment
of opioid use that MMT allows. Her hunch about the efficacy of heroin as a maintenance
medication is supported by recent success of Heroin Assisted Treatment (HAT) in Switzerland
and elsewhere (Fisher et al. 2007; Uchtenhagen, 2010).
Pressure to conform
Casey’s response also illustrates the intense pressure to conform to the dominant
recovery-based narrative. She clearly hesitates before stating her belief that heroin functioned as
a positive in her life, firstly by qualifying her response as “weird” and then by pointing out that
her parents would probably subscribe to the opposite position. Thus the dominant recovery
narrative, continually re-enforces that idea that drug use problems are the result of individuallevel determinants while simultaneously obscuring the social-structural-legal factors.
Correspondingly, social and institutional pressure encourages patients to view their success with
MMT as the result of a medical intervention rather than from the ability of opioid-dependent
individuals to continue using opioids in a decriminalized manner – a narrative far more likely to
lead to policy-based critiques of criminalization.
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Sarah, who has not used illegal drugs in more than seven years, also describes both
internal and external forms of pressure to accept the dominant narrative, despite its inability to
describe her drug use experiences. Although she articulates a complex, nuanced, and multifactorial view of drug use problems, which seems to fall outside of the boundaries of the
recovery model, after taking half an Adderall obtained from a friend while sick at work, she
describes significant stress based on the categories established by recovery discourse. The
interview portion begins with her critique of recovery-based policies – which included pressure
to attend 12-step meetings - at her clinic.
“It was all centered on the idea that you had done something wrong, that you were
in the wrong, that you were this drug addict and you could be making amends for
all these things you’ve done. There was no sense of a drug user being a person.
They didn’t look at anyone’s story, situation, or struggle, which is the reality of
any person, and every person’s story, situation, and struggle is different. And that
plays a part. It plays a part in whether or not a person can be able to go do stuff
[drugs] again, and that be ok. I’m not opposed, I wish I could do that, and I don’t
think there’s anything wrong if I did take a morphine vacation. I know because of
myself and the way that my brain works that I can’t take that chance cause I’m
way happier now. But do I think that’s wrong? God no. You know, this bothered
me so much, cause you know, I haven’t done drugs in, it’ll be almost 7 years, and
I found myself, when I took this half an Adderall and failed this drug test, I’m like
‘Have I relapsed?!’ Like in reality, I haven’t done anything wrong, I was just sick
and took half of my friend’s medication. But I was like, I found myself asking
these questions: ‘Now can I not say that I’m clean?’ and it’s ridiculous and that’s
been so drilled into my head. I have great guilt, I feel bad about it. In the reality I
know I didn’t do anything wrong, I didn’t jeopardize my livelihood or whatever,
and had I not gone through all this drug shit, I would’ve never thought that.”
(Sarah, 2014).
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It is important to note that Sarah’s fears are not based only on abstract ideas about being
“clean” or “in recovery”. Earlier in the interview she described almost losing custody of her two
children after Child Protective Services (CPS) became concerned about her participation in
MMT, in particular, her dose which they felt was too high. The situation was resolved only after
Sarah’s therapist (outside of MMT) assured CPS that she was a good parent and a compliant
patient in recovery. She states:
“I finally learned that I just had to lie. I hate having to do that, but I filled the
ladies head with all the shit she wanted to hear. Used all the buzz phrases she
wanted to hear. Plus I have had to, to protect myself, still stay in ongoing therapy.
[I] Learned real quick it is best to have someone who can attest to your sobriety.”
(Sarah, 2016)
Faith in the medical model
Although for most Negotiators, multiple, and often contradicting discourses seemed to
exist side-by-side, sometimes in an unexamined fashion, one participant explained the
inconsistencies through a sincere belief that a medicalized view of drug use will reduce/eliminate
stigma from drug users. Kerry Wolfe, a long-time MMT patient who self-identifies as a harm
reductionist but also supports recovery hoped that re-framing MMT in terms of recovery might
remove/reduce stigma applied to methadone and people who use it. She saw the push towards
recovery within MMT as a response to the numerous anti-methadone campaigns that were most
active 10-15 years ago. Specifically, Wolfe described how groups like Helping America Reduce
Methadone Deaths (HARMD) – an anti-methadone organization who launched a campaign to
stop people on MMT from being able to drive – had not only sought to marginalize people on
MMT but to substantially deprive them of rights. Similarly, Wolfe described efforts to link
increasing rates of overdose to MMT patients via the suggestion that they were selling their
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medicine on the black market - a claim that has been refuted by Cicero & Inciardi whose study
demonstrates that most diverted methadone originates from pain patients rather than those using
methadone for substance use issues (Cicero & Inciardi, 2005). Thus, Wolfe argued that a
concerted advocacy movement among people on MMT, began to coalesce in order to combat
stigma and misinformation using the disease model of addiction and its corollary focus on
recovery as central aspects of their rhetorical strategy. Although the current focus on recovery
has not been restricted to MMT, Wolfe’s point about the political and social efficacy of the
medical model as opposed to a belief in its validity may be responsible for recovery’s recent
rapid expansion. Echoing this view, Craig Reinarman points out that addiction-as-disease
narratives have risen to dominance, in part because “it is a view that serves useful purposes for
users themselves and for society in general” (Reinarman, 2005: 309).
Moreover, participants based their acceptance of recovery on the oft-repeated dichotomy
between medical and moral approaches to drug treatment that position medical models as
progressive and moral models as reactionary. This binary model not only restricts drug
treatment options to only two, but obscures their often cooperative rather than oppositional
nature. For example, Vic, had used MMT multiple times over a 10 year period, usually to
moderate his heroin and prescription opioid use, and never with a serious attempt at complete
abstinence. He stated that MMT had consistently helped him to survive during more difficult
periods of use, and enabled him to use less drugs throughout. Thus, his experience could be
described as a textbook example of how harm reduction-based treatment benefits drug users.
Yet, Vic was enthusiastic about the growing acceptance of recovery in MMT and when asked
about the disease model, he stated:
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“I do view it, yes, as a disease, and I’m glad that they’re starting to at least take it
more seriously because for awhile they just thought that it was your fault and it’s
on you.” (Vic, 2014).

Conclusion
The recovery model does not reflect the drug use experiences or treatment needs of a
large portion of people on MMT. Study participants’ ages ranged from 22 to 70, and they came
from a variety of racial, class, and socio-economic backgrounds, all of which affected their
perceptions of drug use as well as the relative harms they experienced – though not in clearly
identifiable demographic patterns. Moreover, participants differed in their drug use experience
as well; some had been injecting heroin for many decades while others had been using
prescription opioids orally for only a couple of years. Thus, participants’ views on issues such as
the desirability of complete abstinence, how they defined complete abstinence, the need for a
transformation of self, the role of drugs and/or the state, in their drug use problems, and a
number of other issues were all influenced by a multitude of intersectional variables related to
each person’s individual background, experience, and worldview.
Similarly, participants who had been on MMT for many years or who had used it
intermittently throughout the years described the treatment as fulfilling different functions at
different times in their lives. Many reported pursuing complete abstinence from all substances
during one period on MMT, and using it as a safety net during another. In most cases, their
motivations were a complicated mix of both practical and ideological concerns that reflected that
individuals’ current and past life circumstances. Hence, patients’ accounts of drug use and
treatment conflicted with the recovery model’s linear-progressive narrative and positivist
approach which flattens such distinctions.
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Although institutional proponents of recovery, such as SAMHSA and OASAS touted the
flexibility and patient-centeredness of the model, it was often experienced by patients as
proscriptive and disciplinary. Individuals who conceptualized their drug use histories and/or
treatment goals outside of the recovery model – particularly those who were not seeking
complete abstinence from illegal drugs and alcohol - were likely to encounter institutional
discipline, including the reduction or elimination of their take-home doses (thus forcing them to
attend the clinic everyday), and sometimes resulting in the patients leaving or being discharged
from treatment. While medical approaches to drug use, like recovery, are often touted as
progressive alternatives to more overtly punitive models, both positions locate drug use as a
monolithic and wholly negative activity that must be controlled. Moreover, by constructing drug
users’ choice to attend MMT as unrelated to the ways that they are oppressed under
criminalization, the recovery discourse depoliticizes drug treatment issues, and, as such,
implicitly supports the status quo criminalization of drug users.
These issues occur in part because the recovery model is based on a decontextualized
conception of illegal drug use that ignores the effects of criminalization and the War on Drugs as
a force pushing drug users towards “treatment”. Drug users, particularly illegal opiate users who
are both highly criminalized and marginalized, often engage with MMT as an attempt to manage,
reduce, or potentially eliminate the harms that accompany dependence on a criminalized
substance, and not because of an ideological desire to “recover” from their “addiction”.
However, most drug users in treatment adopt the language of recovery through their interaction
with MMT (or drug treatment in general), where acceptance of the dominant narrative is not only
linked to material benefits, but serves as a protective factor against increased surveillance and
discipline on the part of the clinic.
84

Chapter 5 Talking about recovery: MMT as treatment or refuge
Most of the advocates for drug user rights and services were at least somewhat critical of
the recent shift towards a recovery-based approach to treatment. These were individuals who
currently work with – and in most cases, have long histories of working with – organizations that
provide harm reduction services to drug users (i.e. Syringe Exchange Providers (SEPs),
Naloxone distribution, and education on safe injection practices are primary examples). In many
ways, advocates’ comments were similar to those of participants on MMT who resisted
recovery-based treatment, in that they focused on MMT primarily as a pragmatic refuge from the
harms and difficulties of criminalization, and rejected attempts to conceptualize it through the
lens of the disease model. Similarly, most advocates identified strongly with the nonproscriptive, or value-neutral aspect of the harm reduction philosophy, and saw recovery as
potentially infringing on one of the few spaces (physical, economic and discursive) where
normative beliefs about drug use(rs) were being challenged.
Advocates were most critical of two related aspects of recovery: (a) the recovery model’s
use of science and the medical model to conceptualize drug use/treatment; and (b) recovery’s
proscriptive stance on abstinence and disregard for the many active drug users who benefit from
MMT. However, both of these themes spoke to advocates’ general dissatisfaction with the
recovery model’s failure to acknowledge prohibition/criminalization, both as a leading factor in
the harms drug users’ experience, and as an incentive for drug users to enter MMT. Moreover,
advocates argued that the shift towards recovery-based treatment was occurring alongside a
related professionalization of the harm reduction movement that most saw as parts of the same
inter-related process.
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There were however, two advocates who strongly believed in the recovery movement and
work with organizations that claim to support both philosophies. While these advocates still
considered themselves harm reductionists and argued that the two approaches were not
incompatible, they typically framed harm reduction as a prelude to abstinence which was always
seen as superior. Thus, for these activists, harm reduction was a means of connecting with drug
users, with the larger goal being abstinence-based, and recovery-oriented, behavioral change.
Professionalization of harm reduction
“Selling out is usually more a matter of buying in. Sell out, and you’re really buying into
someone else’s system of values, rules, and rewards” – (Bill Watterson)

Many of the advocates involved with either harm reduction or drug user rights
organizations described the increasing focus on recovery as occurring within a context of
increased professionalization among harm reduction and drug user rights groups. Most felt that
while these groups, who had previously operated as small, often illegally run grass-roots
organizations comprised primarily of active drug users and close allies began to accrue
mainstream acceptance and greater levels of funding, the focus on some of the core principles particularly a neutral or amoral approach to active drug use/rs - became diluted.
Harm reduction activists, particularly those who had been involved with the movement
for a long time, described a dichotomy between an “activist past” and a more medicalized or
public health focused version of today’s harm reduction. Although nearly all of the activists
described harm reduction as being, in many ways, a public health intervention, it was also
conceptualized as having been outside of, and other to, mainstream public health culture and
approaches which were seen by many as stagnant, ineffective, judgmental, and largely unable to
meet or even understand the needs of drug users.
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The role of active drug users in the harm reduction movement
A central aspect of the activist/public health division concerned the level of involvement
of current or active drug users within harm reduction organizations. Advocates spoke
emphatically about the importance of the early days of harm reduction (during the 1980’s and
1990’s) when many of their activities were illegal and organizations were started and led by
active drug users. As long-time harm reduction/drug user rights activist and Vocal New York’s
Policy Director Matt Curtis explains:
“[peer led drug user rights activism has] always been there, it’s the reason we
have harm reduction in the first place. The first Syringe Exchange Program (SEP)
in the world was started by drug users. The first Naloxone program was started by
drug users. All of it. The reason we have supportive laws for this, at least in many
places, is driven by people who use drugs. I struggle to think of a harm reduction
organization that started anywhere from the late 80s through the 90s that wasn’t
started by people with a direct experience of drug use, and often current drug
use.” (Curtis, 2014).
The direct participation of, and leadership by active/current drug users was viewed by
activists as a real world expression of the harm reduction philosophy and part of what
distinguished it from other public health interventions. Bart Majoor, who currently works with
St. Ann’s Corner Harm Reduction similarly described the importance of drug users in harm
reduction’s activist beginnings:
“I entered the field in The Netherlands 35 years ago at the moment harm
reduction was being born there and there were these large groups of [drug] users,
mainly people from outside [of The Netherlands]: the US, all over Europe, and
the problem was, for the first time the government was confronted with a large
group of illicit drug users, which was hardly a phenomenon before that… They
were in the parks, all over the place, homeless, and didn’t want [to] or couldn’t
stop using." (Majoor, 2014).
Most activists felt that drug users are less involved in harm reduction organizations today
and that they had been gradually pushed out of key positions and relegated more and more to
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unpaid, “volunteer” roles. Drug user rights activist Cheryl White describes this historical shift in
“Beyond professional harm reduction: the empowerment of multiply-marginalized illicit drug
users to engage in a politics of solidarity towards ending the war on illicit drug users” (White, ).
She argues that the proliferation of non-drug users in key organizational positions is emblematic
of a co-opted version of harm reduction that is un-willing to critique the structures that produce
harm for drug users. Anthropologist, Gordon Roe agrees, stating: “This ‘official’ harm reduction
saw itself as having matured beyond the sort of activism that engaged in embarrassingly direct
and counter-productive attacks on drug prohibition. It was now much more a career than a
cause, and the political and community voices of harm reduction again became marginalized”
(Roe, 2005: 245)
Thus, activists saw the change as part of a gradually occurring shift over the last ten to
fifteen years as harm reduction became more acceptable as a legitimate public health career path.
Greater levels of accountability, the pressures of increased funding opportunities, and managing
increasingly large organizations combined with a powerful stigma against drug users –
particularly injection drug, and heroin users that form much of harm reductions’ traditional
membership and target population - led to a gradual erosion of active/current/publicly open drug
users in key positions. Curtis explains:
“[active drug user involvement in harm reduction] has changed a lot as programs
have gotten better supported and there’s been a professionalization. An older
generation of folks has died or retired or moved on or been pushed out because
they aren’t perceived to have the technical credentials and skills to lead an
organization as its grown. You can talk about that [active drug use] with your
peers or behind closed doors or at a conference… but you certainly couldn’t talk
about it with a funder or the Department of Health.” (Curtis, 2014)
A less radical harm reduction?
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Activists expressed mixed feelings about the increased professionalization of harm
reduction. On the one hand, it greatly increased opportunities for such groups and programs to
seek out, and receive funding for their efforts thereby enabling them to provide more and better
resources to their target population. Yet, many felt that the changes made harm reduction efforts
less responsive to the needs of drug users and more focused on normative outcomes, such as
reduced levels of drug use. As Curtis points out:
“That’s [harm reduction’s activist roots] a very important part of the history of the
harm reduction movement in the U.S. that gets glossed over or forgotten as we go
on this path towards ‘OK now were going to be doing Medicaid billing and all of
this other stuff that is ‘good’ in a lot of ways because it’s creating more resources
and better things for participants, but ‘bad’ in a way that it definitely creates some
tension with the small, nimble, activist approach which is where you find the real
philosophy or approach of harm reduction…..That ‘Any Positive Change’ model
gets subtly chipped away at the more you’re using some indicator-based program
to do behavior change for your participants.” (Curtis, 2014)
Walter Cavaleri, the founder/director of the Canadian Harm Reduction Network and a
founder of the Toronto Harm Reduction Task Force also expressed a concern that increasing
professionalization could fundamentally alter the nature of what harm reduction is:
“I’ve seen it years ago [harm reduction losing its radical edge] and it’s been
growing and growing, and although I want harm reduction as a concept to be
introduced in every bit of the work that people who use drugs do, I worry that it
becomes rigid and formalized and institutionalized and I saw that happen in social
work which used to be a wonderfully radical profession, [but] has become now
something that is really quite different. It is engaged in becoming more and more
like psychology w/o the really good discipline of psychology. But [it also means
that] ‘hey, I can go out and earn a living’” (Cavaleri, 2014).
Activists linked the professionalization of harm reduction to the increasing use of a
‘recovery discourse’ in drug user interventions through public health’s tendency to focus on
quantifiable outcomes, most often in the form of reduced drug use or reduced of levels of
individual and/or social harms thought to be related to drug use. In an environment where grant
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money is dependent on presenting empirical evidence demonstrating reduced levels of drug use
among participants, harm reduction’s focus on ‘meeting the client where they’re at’ (a central
tenet within the harm reduction community, that requires interventions to not impose a particular
view on their clients’ drug use) becomes difficult to maintain. Majoor explains:
“Originally it [harm reduction] was an approach for drug users who were not able
or capable of stopping their use. [harm reduction is] about normalization of illicit
drug use… [but] Public Health thinking is so un-pragmatic and so judgmental and
so out of touch with reality, that even with loads and loads of evidence –and a lot
of talk of the CDC [Centers for disease Control and Prevention] about ‘evidence
based interventions’, they still deny a large body of harm reduction work and it
absolutely lacks implementation.” (Majoor, 2014).
The increasing professionalization within harm reduction also created (or emphasized) a
tension between more radical elements of the movement who sought to maintain the focus on
active drug use/ers (including a critique of prohibition and criminalization, and ultimately
arguing for the rights of individuals to use drugs as they saw fit), and others who either saw harm
reduction as a way of engaging with drug users in order to promote abstinence or who felt that
the benefits in the form of money and increased opportunities to affect policy justified a certain
amount of compromise.
Taeko Frost, the Executive Director at Washington Heights Corner Project (a NYC-based
harm reduction organization), described the difficulties of working within the two different
ideologies:
“I see that [a distinction between a more radical versus public health version of
harm reduction] all the time. I feel like I’m someone who walks that line every
day. People [on the more medicalized side of harm reduction] talk about ‘in the
perfect world, drugs would be eliminated’ and for me the perfect world includes
drugs and that’s a radical concept…. And so I kind of balk when I hear that….. It
sucks being a social worker or being social work people, you say ‘you try to work
yourself out of a job’, that’s the purpose. But for me, with harm reduction, I’m
never gonna work myself out of a job because, for me, if all of the things we want
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happen [legalization of all drugs; an end to prohibition and criminalization], the
role of harm reduction is still to do what we did at the very core, harm reduction
services would be places where people use drugs together safely. That’s what I
envision if everything gets so medicalized - that harm reduction programs would
shift to be spaces where people used together in a less medicalized way than SIF’s
[safe injection facilities] even. I think it’s great to have RNs and it’s good to have
medical personnel, but I think there are people who use drugs because they enjoy
it, and there are people who are really good at managing their drug use… and I do
think that there’s a space for that. But me as a doctoral candidate in public health
and someone who’s very epidemiologically oriented and runs a public health
agency, I also have seen how in the last 20 years we’re [harm reduction] seeing
this opportunity to be included in this space and I think it would be remiss of us
not to acknowledge that it is an opportunity. I mean, how long can we do this
‘fuck you’ thing?” (Frost, 2014)
Recovery-based harm reduction?
However, not everyone saw the distinctions between harm reduction and more
mainstream public health approaches as oppositional or in conflict with one another. Activists
involved with the recovery movement, saw the increased professionalization of harm reduction
as the vindication of an activist movement through science. Zac Talbott, an activist with
Medication Assisted Recovery Services (MARS), an organization focused on integrating
recovery concepts into methadone and Buprenorphine maintenance treatments explains:
“What we’ve seen is the evolution towards this focus away from just harm
reduction, which is what Methadone was, because we didn’t have the science that
we now have…. Like most medical treatments or like most diseases, we could
effectively treat it before we understood it. So we knew methadone worked, Drs.
Dole and Nyswander figured that out, but we didn’t know why. We knew that it
reduced crime, we knew in the 80’s that it reduced the incidence of new HIV
infections, we knew that it allowed people to get back to life, but we didn’t know
why.” (Talbott, 2014).
Similarly, Ed Manchess Director of Harm Reduction services at Boom Health Care saw
the increased public acceptance of harm reduction in positive terms, particularly through the
ability to access grants and provide clients with more and better services. However, Manchess,
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in contrast to most of the harm reduction advocates in the study, sees promoting abstinence as
part of harm reduction’s mission. He explained,
“The city of New York, the human resources administration is really recognizing
harm reduction as an effective mode of serving individuals that are using drugs or
engaged in other risky behaviors towards living a healthier lifestyle and we’ve
been seeing that more and more in some of the grants that are coming out. In
addition, we here at Boom Health, we believe in recovery and we actually have a
recovery program here, that’s new to the organization, just recently acquired a
grant from SAMHSA (Substance Abuse and Mental Health Services Agency) I
believe. We’re the only syringe exchange program in the country that has this
type of program. It’s a peer-to-peer recovery program. So basically it’s a
somewhat of a social networking strategy where if I were a peer in whatever stage
of recovery, my task would be to recruit other people that may want to change
their life [from] active or semi-active drug use to becoming abstinent from using
drugs.” (Manchess, 2014).
“The program definitely [believes], and other programs are realizing that the
stages of change really applies to so many different aspects, and so many different
types of substance use. It seems to work with everyone.” (Manchess).
Thus, differences between recovery-oriented activists and those who were critical of it
often stemmed from different visions of the harm reduction philosophy and how to best
implement it. For example, while Manchess sees harm reduction as a way of helping drug users
to live “a healthier lifestyle” by moving towards abstinence, his response can also be read as
evincing the diluted character of the movement’s core philosophy. As discussed earlier, harm
reduction was largely brought into being through the efforts of underground drug users and
HIV/AIDS activists as an alternative to abstinence-based models. Yet Manchess clearly
maintains a hierarchical outlook that presumes the universal rightness of abstinence.
Moreover, he describes the mission of peers as one of ‘recruitment’. Although Manchess
insisted his approach is non-coercive, the high stakes and dangerous context of criminalization
problematizes issues of volition in regards to drug users’ treatment choices. Since many drug
users in MMT are motivated by a desire to escape the difficulties of prohibition/criminalization,
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they are particularly vulnerable to coercion. Additionally, the power dynamic between clinician
and patient, amplified by the patients’ physiological dependence on methadone, further
complicates the issue. Frost, who is critical of more proscriptively organized programs, explains:
“That’s something that I see all the time, people get tired of the hustle of
whatever they’re doing and methadone is an option, an option to not be sick,
whether they’re buying methadone off the street for a week, or if they’re actually
getting into a program. I think the criminalization of it really obscures the
purpose, the intention, everything. It’s really hard to parse out how much of it is
what a person really wants when there’s a clear social context of using licit versus
illicit drugs and the implications that has for people getting arrested or just being
tired of doing what they’re doing. I think the criminalization really interferes with
peoples’ ability to make informed choices for themselves and therefore interferes
with their success because they’re not making a decision based on what they want
necessarily, they’re making a decision on trying to get away from the things they
don’t want, and I think there’s a distinction between what somebody wants, and
doing something because you’re trying to get away from things that you don’t
want. And I think that’s what’s happening now.” (Frost)
Summary
Activists’ views on the increasing professionalization of harm reduction were shaped by
ideological as well as practical concerns. Those who saw harm reduction as a way of
normalizing illicit drug use, challenging prohibition/criminalization, and empowering active drug
users expressed mixed feelings about its increased professionalization. While most
acknowledged that greater levels of acceptance, and access to funding enabled harm reduction
services to do more for their clients, they also felt that the movement’s guiding philosophy of
providing services to active drug users without the traditional focus on reducing levels of drug
use had atrophied. The gradual reduction of active drug users, and their relegation to volunteer
roles within harm reduction organizations was seen as exemplifying this shift. Thus, drug user,
and harm reduction activists saw themselves as constantly negotiating between the new
opportunities that increased funding provided and the potential ideological concessions that were
seen as eroding the original philosophy.
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Other activists, who endorsed the increasing focus on recovery, saw the
professionalization of harm reduction in evolutionary terms. The early efforts of more radical
drug user activists were positioned as the first steps that paved the way for today’s more
mainstream version of harm reduction. Science, particularly the neurological brain disease
model of addiction was seen as enabling drug user services to go beyond harm reduction towards
a more professional, medicalized approach that included a focus on drug use as disease and
abstinence (along with recommendations for normative behavioral change) as its treatment.
Although this group of recovery-oriented activists couched their beliefs in the language of harm
reduction, it was generally seen as a way of engaging with drug users in order to move them
towards abstinence which was always seen as the most desirable outcome ipso facto.
Medical/Disease Model
Nearly all of the drug user/treatment activists were critical of the medical model and its
focus on understanding addiction as a brain disease. While they viewed methadone as a
lifesaving medication that improved, and in some cases saved the lives of drug users, they
rejected that this was because methadone treats a chronic brain condition. Instead, most
advocates argued against any universal theory of addiction and viewed the problems drug users’
experience as diverse and multi-factorial but nearly always linked to prohibition/criminalization.
In contrast, those in support of recovery saw the disease model as a scientifically agreed-upon
fact, and viewed it as way of liberating MMT patients from stigma. However, their responses
also suggested that the disease model’s proliferation was linked to the institutional advantages a
disease label would provide such as legal protection and disability funding.
Deconstructing disease
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Advocates firstly rejected the claim that the medical model is, in fact, truly medical.
Instead they argued that while the medical model uses the rhetoric of treatment, it functions in a
paternalistic and punitive manner. Similar arguments have been made about Drug Courts,
another ostensibly medical approach to dealing with drug users (Tiger, 2012).
“We’ve still got prohibition in this country, and we’ve still got a war on drugs,
we’ve got a criminalizing response. And much of the medical model that was
oversold to the American public as an alternative to the moral model is essentially
a criminal model, and therefore it’s still a moral model….. It’s not so much
different from the criminal model because the medical model is still being
perpetrated with this prohibitionist mentality and a War on Drugs, with police
doing everything they can to make life difficult for people who use drugs, and
most of the establishment following suit.” (Bellamy-Taylor)
Additionally, advocates reported numerous problems with the disease model’s
construction of problematic drug use (addiction). Sharon Stancliff, a medical doctor, questioned
the theoretical foundation of the disease model that rests upon the claim that “drugs” alter brain
chemistry. Instead, she argued from a constructionist position that that the categories used to
distinguish between “drug” and “not-drug”; “disease” and “not-disease” were constantly shifting
and culturally determined.
“Some people’s brains probably function better with something different in there,
but probably we all do in various ways…. Does that make it a disease? (Stancliff)
Stancliff was also critical of the recovery models’ theorization of addiction through the
use of vague and subjective concepts presented as science. She was particularly concerned with
how institutionally accepted the relationship between such concepts and drug treatment had
become, noting that the American Society of Addiction Medicine (AMA) referenced “humility”
and “gratefulness” in its treatment guidelines.
“First of all ‘recovery’ is not a medical term. I was just reviewing some guidance
from the American Society of Addiction Medicine on maintenance therapies
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that’s up for public comment, and they’ve got this whole paragraph about
humility and gratefulness and all this stuff. I mean, I totally respect anybody that
considers themself on a path to recovery, in recovery, whatever, I have no
problem with that. But I don’t think it should be a requirement to participate in
those activities in order to receive a life-saving medicine.” (Stancliff).
Stancliff, and others, were critical of this shift, arguing that the increasing institutional
concern with the psycho-social functioned as a barrier between drug users and the services they
need. This was seen as particularly egregious in light of the recent dramatic increases in opioidinvolved overdoses (CDC, 2012) because of MMT’s demonstrated success in reducing their
incidence (Brugal et al. 2005; Capelhorn et al. 1996).
“It seems to me that OASAS (The New York State Office of Alcoholism and
Substance Abuse Services) is going down this path of focusing on the psychsocial, recovery, etc. when we’ve got a, I don’t like calling it an ‘epidemic’, but
we’ve got an opioid crisis of some kind going on, and so we’re out there passing
out Naloxone, and we’ve got all these people that don’t want people to be on
[methadone] maintenance, or [to] have a reasonable time on maintenance - which
is truly the treatment to prevent overdoses - unless they’ll do all the psycho-social
stuff.” (Stancliff)
“Drug use becomes such a part of peoples’ lives in a way that’s inter-woven, that
saying that ‘it’s all bad’ is just completely wrong…. The American Society of
Addiction Medicine and all those kinds of people are never really going to get,
that maybe using drugs saves people’s lives.” (Stancliff)
Similarly, advocates argued that the disease model is reductive and deterministic.
Concepts such as the biological permanence of addiction and necessity of relapse were seen as
inconsistent with the experiences of drug users who, they argued, have much more complex and
nuanced relationships to drug use. Some also referenced a historical process whereby the disease
model has come to dominate over alternative views of drug use leading to a culture of un-critical
acceptance. The following responses are typical of advocates’ comments:
“We’ve had 20, 30 years of this disease model of addiction kind of gaining clout,
and even in a way that’s much more received wisdom than it is really based on an
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accurate understanding of, or incredibly oversimplified understanding of what the
science says about this. Probably if you went back to the 60s or 70s you’d have a
much more, or a somewhat more of a consensus describing addiction, or
dependence as a syndrome that plays out differently with different people, [one]
that has different etiologies. And now, there’s this idea that’s almost
deterministic: chronic relapsing, progression of disease. People don’t even think
about it, they just repeat it.” (Curtis)
“What I still see a lot and what I hear a lot, is the disease model in terms of ‘you’ll
never get rid of it, ‘you might be clean but you’ll still struggle for the rest of your
life’. That’s not what I see, that’s not how I deal with it and I don’t understand
why people who’ve been clean for 37 years still say ‘I’m an addict’ or ‘I’m an exaddict’. You know, why are you doing that? I mean, I just don’t get it. And the
other big elephant in the closet is of course the largest number of people who’ve
ever had a problem with addictions or dependency, in whatever way, know how
to manage it themselves, and you know, either mature out of it, or find some, only
on the weekends, or integrate it. There’s all kinds things that I’ve seen and read
about – I’ve seen a lot of people who use substances in the 35 years I’ve been in
this field, and a lot of them pretty hard core. So I’ve seen a lot of things that have
taught me that it’s not as simple as they try to say. Now when I teach I always talk
about complexity. And that ‘just say no’ and all these models that are propaganda
from the prohibitionist context, that are bullshit, it’s nonsense. It’s a very
complex reality with a lot of sides to it and that’s why I love harm reduction as an
approach because it allows these different aspects.” (Majoor).
The critique of permanence of addiction was brought to light, culturally, in regards to the
fear that American soldiers fighting in the Vietnam War – many of whom had become dependent
on opiates – would come home addicted, causing endless problems for their communities and the
country at large (Robins, 2006). In actuality, upon returning home, most of them simply quit on
their own, casting doubt on pharmacologically deterministic theories of addiction.
Activists were critical not just of the disease model, but of the need for any model to
explain addiction, a concept most saw as problematic to begin with. They argued that the
problems drug users experience were so diverse, and affected by so many variables, that any
model which sought to explain them all, would inherently be reductive. Additionally, they
pointed out that such models typically function as a form of othering, or a way distinguishing the
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“acceptable” from the “unacceptable”. Their comments often aligned with constructionist and
post-structuralist critique which problematizes the use of fixed and bounded categories to
understand phenomenon.
“I think you’ve got to look at the whole need for a model and what’s that about.
Why does it have to be fixed when everything is in flux and always changing?
But more importantly, you wouldn’t want a model that differentiates me from
you, or us from them, which only reinforces the tendency to speak of addicts and
alcoholics as somehow different from everyone else.” (Bellamy-Taylor)
“I think that’s [recovery] in a way, a spinoff of the whole medicalization of what
is called ‘addiction’ – another term I’m not comfortable with – that the
dependence on drugs, and sometimes ‘misuse’ of them, the compulsive use of
them, whatever, is really as Zinberg put it, a bio-psycho-social problem rather
than just a medical one.” (Cavaliere, 2014)
Some also pointed out that many of the problems endemic to the disease model stem
from the ways that drug users have traditionally been studied. For example, Matt Curtis pointed
out that studies are often based on convenience samples drawn from treatment programs, thereby
leaving out the vast number of drug users who either quit on their own, or who maintain nonproblematic relationships with drug use. This, he argues, creates a highly biased, and misleading
picture of drug use and drug users.
“Part of it has been like a positive intention to de-stigmatize people, like ‘it’s not
their choice that they’re doing this’, ‘they’re not bad people’, ‘it’s a brain
disorder’, or like it’s genetic. There’s all this kind of stuff that props up the idea
that is well intentioned and that people also think has something to do with
science. But, it makes it incredibly over-simplified and I think very distant from
what a lot of individuals experience in their own life and their own relationship to
drugs. We know through the scientific literature, although it always gets swept
aside, the vast majority of people who develop some problem with their drug use
stop or moderate on their own. But we have this clinic bias where the population
that’s getting studied the most, obviously is not those people – the 70 or 80
percent of people who never need treatment, because they’re not in contact with
those researchers who are all using convenience samples of people on methadone
programs or rehab centers or syringe exchanges.” (Curtis)
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Curtis’ statements are supported by Craig Rienarman’s Foucauldian-influenced work on
understanding the disease model as a historically situated, cultural project. In “Addiction as
Accomplishment” he argues that rather than emerging from the “natural accumulation of
scientific discoveries”, the disease concept was “invented under historically and culturally
specific conditions, promulgated by particular actors and institutions, and internalized and
reproduced by means of certain discursive practices” (2005: 308).
Efficacy of the Disease Model
One of the primary claims voiced both by advocates and patients who support recovery is
that conceptualizing addiction as a disease will remove stigma from people on MMT. As
discussed, people on MMT programs often experience high levels of stigma, sometimes resulting
in loss of employment, family problems, and the need to keep one’s status as a person on MMT
secret (Conner & Rosen, 2008; Earnshaw, Smith & Copenhaver, 2013). Scholars have mixed
views on the advantages of a medical designation in regards to stigma. Some argue that it can be
beneficial by providing “access to the ‘sick role’, institutional recognition, access to services, and
resource allocation” (Burke, 2011: 188). Recovery advocate Zac Talbott argued from this
position stating:
“Every case we win for methadone patients in court, every time we win against a
community that is trying to prevent a clinic from opening, would not happen if it
were not a disease. Because the powers that be.. that’s why it’s a disability, that’s
why the ACA (Affordable Care Act) protects patients. The vast majority of
effective advocacy we’ve accomplished is because it has been proven. And that’s
why we want to be referred to as patients. Clients don’t have patient protections
or patient rights.” (Talbott)
Interestingly, particularly in light of Reinarman’s analysis, Talbott’s response seems to
conflate the scientific validity of addiction-as-disease with the social/cultural/legal advantages
that accompany that designation. While the two positions are not mutually exclusive, his
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statements align with the work of scholars who focus on the disease model as a rhetorical
strategy rather than ontological reality (Szasz, 1961).
In contrast, while most advocates acknowledged the institutional advantages of the
medical model, they saw it primarily as means for exerting control over drug users and providing
support for the War on Drugs. Some also rejected the claim that conceptualizing drug use as a
disease would reduce stigma for drug users. They pointed out that while the disease model has
been culturally dominant and institutionally accepted for more than a decade, people on MMT
remain highly stigmatized.
“The disease model so hasn’t [liberated people from stigma] for all of the reasons
we’ve been talking about…. it hasn’t, it just hasn’t happened. (Bellamy-Taylor,
2014)
MMT and Active Drug Users
“Whether a particular act is legal or illegal depends on what we call it.”
(Thomas Szasz, 2007)
Most advocates were highly critical of the recovery models’ focus on abstinence, and
contrasted it with what they argued was harm reduction’s value-neutral approach to treating
people who use drugs. Although they were supportive of individuals who chose to pursue
abstinence, they rejected its elevation from personal choice to treatment model or institutional
policy. This, they argued, established a proscriptive approach that is highly removed from the
actual experiences of criminalized drug users who are often using MMT to manage the harms of
illegal drug use rather than to stop using drugs entirely. Activists’ descriptions of illegal drug
use as a difficult and dangerous activity that pushed drug users towards treatment were very
similar to the first-hand accounts of drug using participants. Moreover, they pointed out that
recovery’s monolithic approach to treatment is both reflective of, and reifies the proscriptive and
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punitive models harm reduction seeks to dismantle. Some of them summarized the issue, as one
of: ‘harm reduction incorporating recovery, but recovery not incorporating harm reduction’.
MMT as protection from criminalization
Activists began by pointing out that much of the harms associated with drug use are
either directly related to prohibition/criminalization or are made substantially worse through that
context.
“That’s the first thing you see in everyday life [of drug users] is the damage, the
harm done by the prohibitive context. The police, the courts. If there’s one thing
that’s damaging, it’s the prohibitive drug context.” (Majoor, 2014)
“Most of the folks who do use drugs for one reason or another are forced
therefore to spend so much time and money on the pursuit of drugs, because
they’re illegal, overpriced, all of that stuff.” (Bellamy-Taylor, 2014)
“So many people I have met over the years have really been using drugs quite
sensibly, using them to get better health. But so many spanners are in the way
when they do that: the laws, the quality of drugs, the strength of drugs, the stigma
of drugs and drug use, that it’s hard for them to do what they need to do to be
healthy.” (Cavaliere, 2014)
Consequently they emphasized the protective factor that MMT affords active drug users
(and drug users who are ‘clean’ i.e. only using methadone), particularly against harms associated
with criminalization. Most stated that in their experience, the majority of people on MMT are
not pursuing complete abstinence from all substances, and that many are not even pursuing
complete abstinence from illegal opioids. Rather, they argued that participation in a MMT
program provided active drug users with a safety net against the regular occurrence of
withdrawal as well as the greater likelihood of risky behavior that accompanies it. Activists also
pointed out that MMT releases drug users from having to procure illegal substances multiple
times each day and the associated risk of arrest it brings. Thus, MMT was primarily seen as a
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pragmatic means of decriminalizing one’s life in order to avoid the marginalization and dangers
that accompany illegal drug use. As Majoor explains:
“It [MMT] has nothing to do with abstinence, it has everything to do with not
being sick. It’s a daily, safety protection to be sure that you don’t get dopesick.”
(Majoor)
“It [recovery] really shouldn’t be there – it’s a methadone maintenance program
and it’s a great harm reduction intervention in the sense that it reduces a lot of
harm compared to shooting up 4 to 6 times a day, having to run around. I think
it’s a great intervention, it’s proven to be a great intervention. It’s the context of
prohibition that creates this push towards abstinence.” (Majoor)
To support their position, activists referenced the abundance of evidence-based studies
that demonstrate the efficacy of MMT in regards to reduced levels of HIV/AIDS transmission,
overdose, and prisoner recidivism (Drucker et al. 1998; Langendam et al. 2001; Gibson, Flynn &
McCarthy, 1999), and that the program works particularly well when delivered in a ‘low
threshold’ context that tolerates participant drug use (Brugal et al. 2005; Langendam et al. 2001;
Ameijden, Langendam & Coutinho, 1999).

Similarly, advocates contrasted the early experiments with MMT - which focused on
promoting stability rather than abstinence - with the current standard of care. They argued that
Drs. Dole and Nyswander, who did the foundational research on MMT in the 1960’s saw the
program as a means of reducing harm in the lives of drug users and not as a tool for promoting
abstinence.
“When you read all of the studies on methadone, Naltrexone (which I hate),
Buprenorprine, most of the people in the studies didn’t stop using all of their
drugs, or even opiates. They weren’t thrown out because it was a study and then
we take it into the real world and tell people that they should stop all drugs or get
kicked off. It just doesn’t make any sense” (Stancliff)
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I talked to [name deleted] who was part of the Federal Committee who created the
rules on MMT, and he told me that originally the urine checks were really meant
to inform the councilor at the methadone clinic about other use so that they could
talk about it, and absolutely not in a punitive context. And that’s because of the
prohibition context - it turns into something else.” (Majoor).
As discussed in the previous section (Professionalization of harm reduction), activists
consistently referenced a process whereby data collected for informational purposes becomes refashioned as a means of imposing hierarchies, labels, and control. This was linked to
prohibition, but also to less visible processes of medicalization that are driven, in part, by the
need for quantifiable results. For example, many advocates pointed out how government and
nonprofit monies are intimately linked to an organizations’ ability to quantify their outcomes
hierarchically. Frost acknowledged the possibility that it may be impossible for organizations
linked to mainstream forms of funding to maintain harm reductions’ values:
“That’s been a huge challenge for harm reduction, is like defining what our
outcomes are. And it’s because it’s built on an anonymous services, because
there’s so much stigma attached to active drug use so you have to keep it
anonymous which means you’re not following people for a long time, you don’t
have the traditional type of clinical/medical records, or biomarkers like urine tests
or whatever. And, the goal is not to work towards abstinence, the goal is
individually defined, sometimes on a day-to-day basis. So how do you develop
outcomes on something that is so individually defined? You know, harm
reduction operating from a truly, truly, truly, patient-centered model and based on
anonymous services has been why harm reduction has been so successful, and
also the reason why we haven’t really been accepted… and so I think the
tendency to medicalize comes from that, where it’s like ‘ok if we medicalize, we
can start counting things and reporting things because it’s not enough to give
testimony after testimony after testimony, it’s just not the way that the money
works.” (Frost, 2015)
The need for a nuanced model
Advocates also relied on their own experience working with drug users to point out the
problems with the recovery model which they saw as reductive and potentially dangerous for
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drug users. They were critical of the models’ clear delineation between acceptable behavior
(recovery) and unacceptable behavior (any “drug” use), and argued that a more nuanced model
was needed to account for the variety of ways that people use drugs.
“I think there’s a whole bunch of people who are lazily adopting, or because they
believe it, adopting the more recovery-oriented approach, and see it as like a
failure of either the patient or the treatment or something if people are continuing
to use drugs even if it’s a kind of ‘chipper’ [opioid user who only uses
occasionally in order to not develop a physical dependence] kind of thing. Which
is crazy, I mean it’s the whole problem with abstinence-based rehab… You’re
setting it up in such a way that ‘relapse’ becomes a bigger deal than it should be,
because it’s like an event and now you have to start over again. [smacks hand into
palm for emphasis], and it’s really setting the person up to be like ‘well if Im
gonna use again, I guess I’m just gonna use again’, it’s not like a moderation
thing where that might be okay for that person and healthy and certainly a lot
healthier than completely going off the rails.” (Curtis)
“I don’t even know what recovery means anymore. I think if a person’s life
situation and health, physical and mental health, improves, that’s recovery.
Recovery to me is not a totally abstinent-[based] entity. In fact, that may be the
most harmful thing for some people.” (Cavaliari)
The focus on abstinence among methadone providers also limits the ability of harm
reduction organizations to provide maintenance (either Methadone or Suboxone) to their clients.
Frost, who runs a NYC based harm reduction center, explains:
“That’s a service that we know people need, but we can’t bring in a provider
whose not willing to do treatment for people who are active drug users. There are
some doctors who just won’t treat people who are active drug users so we would
have to make sure that the provider understood that they were providing services
in a harm reduction way…. I think with drug treatment on-site, I would have the
same type of questions for a provider – it would not make sense to bring in a
provider whose going to be, you know, doing urine screens every time they come
in. Is there a provider that’s willing to work within that? How comfortable does
the provider feel if they start feeling confident that the participant is selling their
suboxone to buy dope?” (Frost)
Instead, many advocates argued for a “low-threshold” approach to treatment. The term
low-threshold is sometimes used synonymously with harm reduction based treatment services
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and generally refers to clinics whose goal “is not necessarily to eliminate illicit drug use but to
establish and maintain contact with opioid users to reduce some of the health and social risks
associated with drug use” (Millson et al. 2007). Although there are different approaches to lowthreshold treatment, common features include: the removal of admission waiting lists; less
punitive (or non-punitive) responses to participant drug use; and a willingness to allow clients to
be maintained on low doses which allow individuals to better experience the euphoria of shortacting, illegal, opioids.
“We have several programs around the province of low-threshold methadone I
don’t know whether you have them in the United States – where you don’t have
as many piss tests, and where they don’t kick you out if you’re using cocaine.
They really do their best to keep you somewhat stable. (Cavaliere, 2014)
“We need to lobby, to use our power, which is basically that we have an
incredible link to the client, and use that as leverage to organize services that are
really low-threshold, and of a quality that the participant wants, and not what the
medical establishment wants.” (Majoor, 2014)
MMT as decriminalized opioid use
The need for, and existence of, low-threshold clinics directly addresses the tension
between understanding MMT as a form of “drug treatment”, and understanding it as a strategic
refuge from the forces of criminalization. That MMT patients remain using, and are physically
dependent on opioids (methadone) problematizes most conceptions of addiction and treatment
that are based on clear distinctions between “drugs” and “not-drugs”. Moreover, it suggests that
MMT’s efficacy is not pharmacologically derived but rather a result of the decriminalized
context of opioid use that MMT affords. The success of individuals on Heroin Assisted
Treatment (DPA, 2016) adds further credence to this argument. Although discourses that paint
MMT as a legalized means of providing “drugs” to “addicts” are generally framed in the extreme
negative and used to de-legitimize the treatment, that idea can also form the basis of a structural
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critique of criminalization. This is particularly the case in light of the numerous studies
demonstrating methadone’s success in reducing death rates, criminality, and transmission of
blood-borne infectious diseases, as well improving health and social productivity (Joseph,
Stancliff and Langrod, 2000; Marsch, 1998; Capelhorn et al., 1996).
Anarchist thinker Hakim Bey’s concept of the Temporary Autonomous Zone (TAZ) is
useful towards understanding the ways that many drug users utilize MMT. Bey describes a TAZ
as “an uprising which does not engage directly with the state, a guerilla operation that liberates
an area (of land, of time, of imagination) and then dissolves itself to reform elsewhere before the
state can crush it…..the TAZ can ‘occupy’ these areas clandestinely and carry on its festal
purposes for quite a while in relative peace.” (1985: 101). Thus, TAZ’s, like harm reduction
itself, are pragmatic strategies for exercising freedom and autonomy within a punitive landscape.
Since both philosophies start from the position that systems of power and control should be
resisted, concepts of rule-breaking or deviance are re-cast, both as pragmatic means of survival,
and as ethical responses to power. Thus, “illegal immigrants” who get married to remain the
United States, poor people who engage in food stamps fraud, and drug users who use MMT to
gain a quasi-legal supply of opiates are operating within a context of TAZ. Advocate, Walter
Cavaliere’s comments reflect this view:
“They [drug users] want to build a better world for themselves, for others, and for
the world in general. [There are] Some things that the drug user does that I as a
[harm reduction] worker cannot do, at least at the moment. I can’t hideout a
person that is hiding from the police, I can’t run a safe drug-use site in my home,
or other things as well, I can’t or I choose not to take drugs into prison. I don’t
want to get myself in trouble. Those are harm reduction things that the drug user
uses and I think need to be explored more. What is lacking in harm reduction, and
maybe what is lacking in the whole recovery movement is a real understanding of
the restrictions put on people by nature of the illegality of what they do, and what
they’re forced to do because of that illegality. This can never be resolved and the
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recovery people can never be completely recovered in my terms, meaning a better
life, until the drug laws are changed to reflect reality.” (Cavelieri)
In line with this view, most activists sought to make MMT as low-threshold as possible
by offering individuals a full range of options outside of an abstinence-based context.
“If someone doesn’t want to or cannot stop [using opioids] at this moment, well
what does he or she want? Clean syringes? Other paraphernalia? Information?
Fine, that’s it. That’s what you give him.” (Majoor)
“If there’s people that really just want to come and get their methadone, let them.
If people don’t want a higher dose because they still want to use, let them. Keep
them coming and keep them safe, because they’re safer.” (Stancliff)
Not surprisingly, the recovery-oriented advocates rejected this view, arguing instead that
clinicians should be encouraging drug users to move towards abstinence. Perhaps ironically,
considering harm reductions’ origins as an alternative to abstinence-based treatment, this
position was framed by proponents as “harm reduction”. For example, Ed Manchess, program
Director at a NYC harm reduction center, stated:
“Some of them [methadone clinics] are becoming more interested in harm
reduction, not just in the sense of dispensing methadone as a way of stating that
they practice harm reduction, cause I don’t really think that’s a practice of harm
reduction. I think the practice of harm reduction is more in the dialogue you have
with someone and how you may use some type of interviewing techniques or
motivational techniques, getting someone to foster change, rather than coerce
people to change.” (Manchess)
Manchess’ conception of harm reduction is particularly interesting in that it suggests a
complete re-fashioning of the value-neutral approach of ‘meeting drug users where they’re at’
towards a program meant to foster individual-level, abstinence-based, behavioral change.
Similarly, his distinction between “getting someone to foster change” and coercion functions as a
rhetorical slight-of-hand designed to mask the proscriptive approach of his organizations’
practices. When understood in regards to the power dynamic between clinician and drug user his
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suggestion that his approach is either non-coercive or a form of harm reduction seems difficult to
support.
Conclusion
Most advocates were highly critical of the increasing use of recovery to conceptualize
MMT and saw the shift as occurring alongside the emergence of a less radical iteration of the
harm reduction movement. Specifically, advocates argued that the medical/disease model that
undergirds most recovery rhetoric was both highly reductive, and problematic in its ability to
obscure the role of prohibition/criminalization as a negative force in the lives of drug users.
Similarly, most advocates criticized the recovery models’ proscriptive stance on abstinence
which they pointed out was inconsistent with the realities of drug users who often use MMT to
manage the problems associated with criminalization; in some cases, using the program as a
means to gain stable, affordable, and most importantly, legal access to opiates outside the context
of the War on Drug (users). Thus, advocates used paradigms of resistance to explain the ways
drug users utilized MMT and saw recovery as part of a regime of social control linked to the War
on Drugs.
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Chapter 6 Discussing Recovery

This study uses qualitative data, supported by my own experience as someone who used
illegal opioids and as someone currently in methadone maintenance treatment (MMT), to
critically examine the increasing use of ‘recovery’ to conceptualize and organize the program. It
argues that recovery in this setting is based on a decontextualized understanding of illegal drug
use that ignores criminalization and the War on Drugs (WOD), both as a source of harm in
people who use drugs lives and as driving forces in their treatment decisions. Moreover, by
constructing drug users’ choice to attend MMT as unrelated to the ways that they are oppressed
under criminalization, the recovery discourse depoliticizes drug treatment issues, and, as such,
implicitly supports the status quo criminalization of people who use drugs.
How well do the tenets and claims of the recovery model align with the experiences of
individuals in the program?
MMT as a means of reducing harm
In contrast to the medicalized narrative of the recovery model that positions MMT as a
form of treatment for addiction, most participants (from the MMT-client group) described their
reasons for pursuing MMT in pragmatic terms related to the structural context of criminalization.
Specifically, they focused on the practical difficulties of having to regularly acquire illegal drugs,
and related problems when their efforts were unsuccessful. Most notable was their use of MMT
to avoid withdrawal which was seen as problematic not only because of its extremely unpleasant
effects, but because of the inability to work, stay in school, or pursue non-drug related activities
when periodic sickness was a regular occurrence. Participants also reported dangers associated
with the police and criminal justice system, as well as the high prices, unregulated drugs, and
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unreliability and constant chaos of the illegal market as additional problems. These difficulties
were seen as having a synergistic quality that made dependence on an illegal substance an
unsustainable lifestyle.
Participants described MMT as alleviating these problems by providing a means to
safely, affordably, and reliably acquire opioids outside of their criminalized context. They
specifically emphasized the pragmatic advantages of MMT, such as stability, legality, and the
elimination of withdrawal. This not only reduced or eliminated the difficulties and dangers
associated with illegal opioid use, but allowed them the time and stability to build a life free of
the need to constantly seek out drugs. Thus, participants contrasted the constant hustle, dangers,
and chaos of illegal drug use with the relative ease and stability of MMT.
Similarly, and in-line with most participants’ (from the MMT-client group) view of
MMT as a means to reduce or eliminate the problems associated with illegal opioid use (the only
class of substances that methadone treats from a pharmacological perspective), many were not
interested in abandoning substance use completely. Some wanted to use illegal opioids less
often without quitting entirely, while others wanted to quit using illegal opioids but continue
using other substances (most often alcohol or marijuana). Most participants found the focus on
addiction generally, and the ability to police a wider range of substances that it enabled, to be
counterproductive, demoralizing, and a barrier towards joining the program to others not
currently involved in treatment.
These results align, to some extent, with those of McKeganey et al. (2004)’s examination
of whether drug users in treatment are seeking abstinence or harm reduction. Although that
study is framed as demonstrating their preference for abstinence, the results show that
individuals in MMT, as opposed to other types of substance use treatment, were the least focused
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on achieving abstinence – only 42.5% reported seeking only abstinence (as opposed to harm
reduction only or a mix of abstinence and harm reduction). It is likely that the percentage is even
lower due to social desirability bias. Similarly, Fisher et al.’s examination of drug users’
perceptions of MMT emphasizes the pragmatic benefits people who use drugs accrue through
not having to participate in the illegal drug market (2002). Some of the participants’ responses
sound remarkably similar to those in this study. For example, one stated, “As long as I don’t
have to find or chase heroin, I would be able to function. Methadone is the solution for me.”
(2002: p. 507) Similarly, many participants in that study were not pursuing complete abstinence
but used MMT as a way of minimizing (sometimes temporarily) the harms associated with
illegal opioid use such as withdrawal and having to commit crimes to avoid withdrawal (2002).
Similar to the participants on MMT, most of the advocates I spoke with also
conceptualized MMT as a means of reducing harm rather than as a means of achieving
abstinence-based recovery (though most felt that a good program should offer participants either
option, or anything in between). Many saw the harms that they encounter as directly caused by,
or related to prohibition/criminalization, and emphasized the pragmatic benefits associated with
using a legal, rather than illegal substance. In general, activists’ accounts of how and why
people use MMT, as well as how they benefit from it, aligned with those of the MMT clients
themselves. Thus, among the three participant groups, only the clinicians/treatment providers
argued that MMT was primarily about recovery, and even some within this group admitted that it
was out-of-synch with how many people utilized the program.
Reliance on normativity
The recovery narrative’s reliance on normativity and lack of appreciation for the
structural divisions in society also problematizes its ability to represent a highly diverse
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community like people who use drugs. Although recovery is conceptualized institutionally as an
uncomplicated (and even objective) diagnostic entity, since the definition includes things like
work, school, and being perceived as a good citizen, it obscures the hierarchical nature of our
society where access to monetary and other forms of capital are dispersed unevenly and often
along racial and class lines. For example, since African Americans and Latinos are less likely
than whites to be employed (US Dept. of Labor, 2016), they will be similarly disadvantaged in
regards to assessments of recovery. Even things like accents, choice of clothing, or bodily
comportment signify and reflect social hierarchies (Bourdieu, 1984) and can therefore affect
assessments of recovery. Thus, by linking addiction to such vague and subjective markers as
choice of friends, good citizenship, and/or maintaining the “right attitude”, recovery becomes a
powerful tool for the enforcement of norms, and the maintenance of social hierarchies.
Notably, some participants did describe their drug use experiences and treatment
motivations through the lens of recovery. These individuals – who often identified as being in,
or pursuing recovery – used medical language to frame their difficulties with drug use, and saw
MMT as a form of medical treatment. However, many in this group relied upon subjective and
culturally specific interpretations of “abstinence” and “drug” that problematized recovery’s use
of discreet and universal categories to delineate between people in recovery versus those who are
not. For example, participants who occasionally drank alcohol tended to view that as within the
bounds of recovery but rejected recreational marijuana use. Others smoked marijuana and
argued for its acceptability while dismissing the claims of those who drink.
Although not everyone who identified as being in recovery defined it in exactly the same
way, the divisions between those perceived to be in, or pursuing recovery versus those using
MMT as a form of harm reduction, was a significant source of tension. Recovery-focused
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participants felt pragmatically-focused clients were giving the program a bad name and
potentially even jeopardizing its existence. In some cases, this led to a tense clinic atmosphere,
sometimes involving clients reporting on one another for drug use or other activities that conflict
with recovery. Since the recovery discourse is involved in expanding the jurisdictional
boundaries of addiction-causing substances and behaviors, one can imagine how debates over
substances like cigarettes, chewing gum, and sugar, or behaviors such as playing the lottery can
further complicate the already tenuous boundaries between recovery and active addiction.
It is important to keep in mind that individuals in MMT are operating within an
institutional environment that rewards acceptance of recovery and punishes deviation from it.
Scholars have pointed out the capacity of such institutions to promote the internalization of their
own norms and values (Foucault, 1973; Goffman, 1968; Szasz, 1961). Thus, while not denying
the lived experience of individuals who see their experience as medical treatment, recovery in
MMT engenders an institutional process whereby “addicts” learn to describe their newly
reconstituted life stories utilizing the linguistic rules of the disease/recovery discourse
(Reinarman, 2005). Sociologist Helen Keane points out that medical categories are particularly
imbued with this type of power, stating:
“Therapeutic authorities work in the service of liberty and personal choice, which
ironically makes them more profoundly subjectifying than other more obviously
oppressive forms of authority. Therapeutic authorities seem to emerge from inside
ourselves, from our desires for happiness and striving for fulfillment. The
understanding of freedom as a regulative norm provides a useful insight into
recovery discourse, which urges troubled individuals to attain autonomy and find
happiness through open-ended projects of self-examination and selfimprovement” (Keane, 2002)
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Conclusion
Most participants conceptualized, and utilized MMT, primarily as a way to moderate or
potentially eliminate the harms and difficulties of illegal opioid use and not as an abstinencebased program of self-change. This not only contrasts with the recovery narrative, but with
disease-focused, and pharmacologically deterministic theories of addiction generally. Instead of
acting at the behest of a substance or mental illness, participants’ experiences can be better
described as those of highly criminalized individuals (often with additional intersectional forms
marginalization and/or oppression) who are often forced to make strategic decisions under
difficult circumstances. For some, this meant utilizing MMT to permanently reduce a variety of
risks without having to discontinue opioid use (methadone) - essentially swapping an illegal drug
for its decriminalized cousin - though most would not frame their activities in that way since
discourses that position MMT as a form of ‘substitution’ are culturally associated with antimethadone arguments. For others MMT functioned as a temporary means of survival during
particularly difficult circumstances. In either case, their actions demonstrated a rational form of
strategic adaptation to oppression – a narrative that sharply contrasts with the medically-based
tenets and claims of recovery.
Thus, one important finding of this study is that the narrative of recovery-based treatment
is not universal to all people on MMT. Although many are undoubtedly seeking recovery, many
clearly are not, and these already marginalized individuals become increasingly marginalized by
having to conform to its tenets. This is particularly important in light of the long history of
silencing, and ignoring the voices of people who use drugs in regards to their own perceptions of,
and needs for treatment (Chen, 2011; Friedman et al., 2007; White, 2001).
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How, if at all, has the shift towards conceptualizing MMT as recovery-based treatment
affected issues of agency and control among individuals in the program?
An individualist model?
Although treatment providers and individuals working for administrative offices like
Substance Use and Mental Health Services Agency (SAMHSA) and New York Office of
Alcohol and Substance Abuse Services (OASAS) consistently described recovery as a flexible or
“individualist” model that was easily adapted to meet a variety of needs, interviews with
participants from the MMT-client group refuted this claim. Rather, most described clinics as
decidedly top-down institutions that maintained strict rules and used punishment to back them
up. Although they pointed out that clinics have always been authoritarian in structure, recovery
expanded their jurisdictional boundaries, allowing them to intervene in more aspects of their
clients’ lives. Moreover, it provided a strong ideological motivation/justification - through the
disease model of addiction - for them to do so.
The ability of individuals in MMT to participate in or otherwise structure their treatment
depended on how clinic staff perceived them in regards to recovery. Clients whose treatment
goals aligned with the recovery model reported few if any problems dealing with their clinics,
and often saw their counselors as allies in their recovery. However, participants whose treatment
goals contrasted with recovery, for example individuals utilizing MMT for harm reduction and
not abstinence, reported numerous difficulties. This is particularly important considering that
most participants’ (from the MMT-client group) descriptions of how they used and benefited
from MMT, aligned far more closely with the open-ended, and pragmatically-oriented harm
reduction model than with the strictly delineated tenets of recovery.
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Clinicians generally saw individuals who were not pursuing recovery as either unready
for treatment or as taking advantage of the program and hurting those who were using it
“correctly”. Twenty years ago Koester et al. rejected this all-or-nothing interpretation in their
qualitative study of what motivates people who use heroin to enter MMT (1999). Instead, they
characterize MMT as a pragmatic strategy utilized in multiple ways by a highly criminalized
population with limited options. More recently, Harris & Rhodes point out that within the
context of numerous constraints that restrict people who use illegal drugs and people on MMT,
even activities generally understood as rule-breaking or crime, such as diverting methadone to
the illegal market, can be understood as “indigenous harm reduction strategies” that help people
who use drugs to “manage their drug use, prevent withdrawal, cement social relationships, and
inadvertently protect against hepatitis C transmission.” (2013: p. 43)
Although some treatment providers emphasized that their clinics’ focus on recovery was
non-coercive, this position seems untenable. Firstly, recovery-oriented goals and principles are
often built institutionally into programs (SAMHSA, 2015; SAMHSA, 2009) as well as conveyed
through the client/counselor relationship. This was evidenced by the interviews with SAMHSA
and OASAS employees who stressed the organizations’ focus on recovery-based treatment, and
who described a number of recently implemented recovery-based programs and grants.
Secondly, the belief that individual clinics can provide a non-coercive focus on recovery also
misunderstands the highly unequal power dynamic between individuals on MMT and treatment
providers. People on MMT are often terrified of being discharged from programs, which makes
any official doctrine on how to conceptualize drug use and treatment, coercive. Moreover, some
treatment providers were upfront in their belief in the disease/recovery model, and that people in
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their programs were encouraged to adopt it and describe their drug use through those concepts
and language.
Surveillance & Punishment
Individuals in MMT who were not in, or were not pursuing recovery associated the shift towards
recovery-based policies with an increased focus on policing their drug use. Although clinics
have always maintained rules against substance use (SAMHSA, 2015; Joseph, Stancliff &
Langrod, 2000), the culture of recovery involved a greater emphasis on abstinence. Thus, while
in the past, clinics may have tolerated their clients’ substance use, seeing MMT as, in part, a
form of harm reduction, this is less and less common (or acceptable) in the environment of
recovery. Since clinics have significant autonomy and policies often vary by individual clinic, a
clinic director or counselors’ views on recovery versus harm reduction, can significantly affect
their rules and policies.
Some administrators even directly mentioned harm reduction as something that would
no longer be tolerated. Moreover, since recovery conceptualizes addiction as a holistic, or
whole-person problem, clinics are increasingly focused on clients’ non-opioid substance use
which had, in the past, often been seen as outside the purview of MMT.
Punishments most commonly took the form of reducing or eliminating individual’s takehome doses. Since this meant having to attend the clinic every day (with the possible exception
of Sunday when most clinics are closed), it was a serious penalty that made life much more
difficult for such individuals. Moreover, the highly limited, early morning dosing hours
exacerbated this problem. Thus, such policies inevitably forced individuals to spend a
considerable amount of time (often during standard working hours) at their clinic, making it
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extremely difficult for these already marginalized individuals to maintain regular employment.
This is particularly problematic when considering that most people reported using MMT to
stabilize and/or normalize their lives, a nearly impossible outcome under such circumstances.
Not surprisingly, the punitive structure for take-home doses was among the most
contentious issues (particularly for those not receiving them) and many reported it as the main
reason for having left a particular clinic, or treatment in general. Studies demonstrate that
individuals who leave MMT often return to more risk-involved forms of street opioid use
(Fugelstad et al. 2007; more). For example, Fugelstad et al. found mortality rates from unnatural
deaths (usually overdose) of 44.3% for individuals discharged from MMT programs as opposed
to rates of 2.1% for those currently in MMT (2007). Emphasizing this relationship, one
participant in this study died shortly after being consistently refused take-home doses and
eventually leaving treatment as a result 16.
Recovery was also associated with an effort to expand the number of services offered
(and sometimes required) by clinics. This shift is reflected in clinicians’ increasing preference
for the term Opioid Treatment Program (OTP) instead of the more specific Methadone
Maintenance Treatment Provider (MMTP). Clinicians emphasized that the program was not
simply a means of providing individuals with methadone, but rather a holistic treatment for
addiction, which was described as a whole-person pathology, requiring a variety of psych-socialspiritual interventions. Examples of recently introduced services included: on-site 12-step
meetings; peer-based recovery groups; and various classes centered on promoting ‘healthy

16
Although it was not completely clear how this participant died, the proximity of his death to his departure from
MMT (within a month), as well as his comparatively young age (early 30s) suggests that the two events were at least
partially related. Research has demonstrated increased risk of overdose, suicide, and a variety of negative health
outcomes associated with discontinuation (particularly involuntary discharge) of MMT (Clausen, Anchersen &
Waal, 2008; Capplehorn et al. 1996).
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living’ such as exercise or ‘more nutritious’ eating. Clients reported that such services were
often included as parts of their treatment plans and that they felt pressured to attend whether it
was officially required or not.
Much of the research on MMT is critical of how excessive rules and regulations affect
treatment outcomes (Stancliff et al., 2002; Des Jarlais et al., 1995; Dole & Nyswander, 1976).
Stancliff et al. cite the restrictive nature of MMT as potentially explaining why so many people
who use drugs view it negatively (2002). Similarly, physicians Dole and Nyswander - who did
the foundational research leading to MMT in the mid-1960s - also rejected the use of strict rules
and regulations, which they cite as the most common reason for “addicts” to reject treatment.
Others point out, that MMT is incapable of providing “individualized” treatment while
maintaining a rigid system of rules (Des Jarlais et al., 1995; more). As Des Jarlais et al. argue
“The highly restrictive regulations also serve to undermine patient morale in MMT. The
complexity and rigidity of the regulations work against the idea that treatment is individualized
according to the needs of the specific patient” (1995: p. 1581). Moreover, aside from the
ethical, and morale-based problems associated with such policies, there is no evidence that they
are effective (Ward, Hall & Mattick, 1999).
Medical model as a form of social control
The disease model also functioned to legitimize the increasing control demanded by
clinics over their clients. In particular, the disease model established the pathological nature of
drug use/rs, as well as the hierarchical social context that positions doctors and clinicians as more
knowledgeable (and better able to determine treatment needs) than drug users themselves.
Scholars focusing on the trend towards medicalization have consistently noted its ability to
restrict the agency of “sick” individuals, ostensibly for their own good (Conrad and Schneider,
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2010; Zola, 1972; Rosenfeld and Faircloth, 2009). Thus since the disease model constructs
“addicts” as inherently flawed individuals’ who are incapable of acting in their own interests, the
use of authoritarian and paternalistic tactics seems justified (Acker, 2002; Szasz, 1961).
Clinic counselors knew that such policies – particularly the expanded focus on nonopioid drug use – would negatively impact many of their long-term, and older, clients. However,
they conceptualized the shift as an inevitable result of top-down policy changes. Moreover, and
in line with recovery discourse, they also saw the changes as positive opportunities for “addicts”
to “treat their disease”, meaning to accept recovery. Thus, clinicians’ attitudes were informed by
discourses of addiction that utilize both medical and punitive elements. Here making the proper
treatment choices was conceptualized as both an opportunity and a responsibility, and difficulties
that arose for individuals who were not pursuing recovery, were seen both as a product of their
disease and also as their own fault. Similarly, (and evidencing how clients’ internalize such
narratives) clients also tended to view punishments as ‘their own fault’ rather than as the result of
punitive and unfair polices. Although medical and punitive approaches are often conceptualized
as mutually exclusive, scholars point out that they are better understood as parts of the same
institutional and cultural structures for controlling people who use drugs, and often work in
support of one another (Tiger, 2013; Smith 2012; Keane, 2002).
Participants reported occasionally voicing their concerns over such policies, however
they were consistently rebuffed using the same discourses of pathology. For example, SAMHSA
and OASAS employees described clients’ requests for harm reduction-based treatment as “their
disease talking” and declared that, if allowed, “addicts” will always try to “lie and manipulate”.
Thus, the medical model established an epistemological dynamic whereby drug users’ views
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were not only devalued and silenced, but positioned as inherently in-authentic and malicious
products of their disease.
Stigmatization
Although one of the most oft-cited defenses of disease, or medically-based theories of
drug use is the claim that such models reduce stigma (White and Mojer-Torres, 2010; more),
participants’ descriptions of recovery-based treatment refuted this view. As discussed (earlier in
this chapter), individuals who used MMT as a form of harm reduction were often stigmatized by
recovery-focused clients and clinicians, who sometimes sought to remove them from treatment
programs. Thus, while not necessarily stigmatized for their disease as such, their decisions
regarding it were morally scrutinized. Arguing from a similar perspective, medicalization
scholar Irving Zola points out, that even if diseases, in and of themselves, do not inherently
represent moral signifiers, once the conversation moves to exploring how one acquired or treated
a particular malady, “then the rational scientific veneer is pierced and the concern with personal
and moral responsibility emerges quite strikingly.” (1972: p. 472).
In Addiction stigma and the biopolitics of liberal modernity Sociologist Susan Fraser
describes stigma as means of mobilizing political power rather than a static marker of difference
(Fraser, 2017). She argues that “we must consider addiction not so much as a stigmatized state
but as a linguistic and taxonomical mechanism by which stigma is materialized. (2017: p. 8) and
that “addiction is a means by which contemporary liberal subjects are schooled and disciplined in
the forms of conduct and dispositions required to belong, and to count as fully human” (p. 8).
Hence, these results align with research that problematizes claims of medicalization as a
liberatory force in people who use drugs’ lives (Kvaale, Haslam & Gottdiener, 2013; Kaye,
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2012; Tiger, 2013; Keane, 2002). Rather than reducing levels of stigma, many respondents –
particularly, those who utilized MMT for harm reduction – described high levels of stigma based
on who was seen to be using MMT ‘correctly’. Thus, while the recovery discourse did establish
a hierarchy that may have reduced stigma for certain individuals, it was at the expense of others
who were increasingly marginalized for their views.
Harm reduction, drug user rights, and recovery movements
Efforts to promote or implement harm reduction-based treatment have also been affected
by the political landscape of drug treatment services and activism. Although harm reduction
overlaps, and is historically aligned with the drug user rights movement, it has also become
increasingly accepted within mainstream medicine, potentially shifting the movements’ focus.
Many of the advocates I spoke with, who still identify as harm reductionists, were critical of the
shift and worried that it has led to a less radical version of the movement. Specifically, they
were concerned that today’s more mainstream harm reduction is necessarily more focused on
normative outcomes like abstinence and less willing to support active drug users. They argued
that a political critique of criminalization, which had always been a part of the movement, is
increasingly ignored. Advocates linked the ability of harm reduction organizations to access
mainstream funding sources to a focus on quantifiable outcomes like reduced levels of drug use.
Thus, they characterized the trend as one of an outsider movement, becoming increasingly part
of the mainstream and, therefore, less equipped to be critical of it.
This shift is also reflected in drug use scholarship where some advocate merging
abstinence-based and harm reduction treatment models (Futterman, Lorente, M., & Silverman,
2004; Kellogg, 2003). Such programs usually call for “building a therapeutic continuum
between the harm reduction and abstinence-oriented treatment worlds” (Kellogg, 2003: p. 241).
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Although proponents often describe such hybrids as incorporating the best of each model,
opponents argue that a “continuum” necessarily preserves the hierarchical relationship between
abstinence and drug use, which harm reduction traditionally opposes. Thus, most hybrid models
relegate harm reduction to a means of initiating (and maintaining) contact with marginalized
drug users, in order to encourage them to pursue abstinence, which is always seen as the true
goal.
Conclusion
Results demonstrate that conceptualizing MMT as recovery-based treatment has a variety
of potential negative effects for individuals using MMT for harm reduction and not recovery.
Participants described an increasing ability for clinicians to intervene in areas of their lives
previously seen as outside of the purview of MMT. This included increased surveillance of their
drug use, and notably, a focus on monitoring use of non-opioid substances. Participants who
were not pursuing recovery often experienced the shift as intrusive and punitive, and changes
associated with recovery accounted for at least one participant abandoning treatment (and
subsequently dying).
The disease model of addiction was used as a justification for increased surveillance and
punishment of people who use drugs as well as a strategy for silencing dissent amongst those
who requested forms of harm reduction treatment. Similarly, participant responses suggest that
rather than a means of reducing stigma among drug users, the recovery model merely re-arranges
how, and to whom stigma is applied – in this case, those who resisted recovery were consistently
marginalized. Thus, the shift towards recovery-based treatment in MMT did not increase agency
and control for people in the program. Moreover, for those positioned as deviant by the recovery
discourse, the change was associated with a significant reduction in their ability to structure their
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treatment, in many cases leading to discontinuation of treatment (either voluntarily or
involuntarily).
How does conceptualizing MMT as recovery-based treatment affect how drug use, drug
treatment, and drug control are understood?
Obscuring structural and institutional oppression
Although medical models of drug use and treatment like recovery are often positioned as
progressive alternatives to more overtly punitive models, the results of this study demonstrate a
more complicated relationship. Rather than an alternative to criminalization, the recovery
discourse in MMT provides implicit support for it by obscuring its role both as a source of harm
in drug users’ lives, and as a motivation for their engaging with treatment (MMT). First,
recovery positions the harms people who use drugs encounter as resulting from individual
pathology, i.e. the disease model of addiction, rather than through the structural-legal difficulties
imposed on them by criminalization. Although nearly all participants linked the difficulties they
encountered using drugs to their illegality, the recovery discourse frames such problems as
resulting individually, from addiction. Thus, the role of heroin’s illegality in the harms and
difficulties drug users encounter is positioned outside of the model and free from critique.
Similarly, the recovery discourse also constructs drug users’ decision to use MMT as motivated
by a desire for abstinence-based recovery, and not as a refuge from the harms of criminalization.
This constrains discussions of drug users’ harms, and of MMT’s benefits, to the
biological/pharmacological, rather than structural-legal domains, thereby depoliticizing drug
users’ treatment decisions.
The false dichotomy between drugs and medicine

124

This obfuscation is accomplished in part by the recovery model’s reliance upon the false
dichotomy between “drug” and “medicine”. By positioning methadone as a medication, with
little to no relationship to illegal opioids like heroin, the recovery discourse describes positive
treatment outcomes as the result of a pharmacological intervention: switching from a “drug” to a
“medication” rather than from an illegal substance to a legal one. This construction not only
renders the treatment more politically acceptable, but also enables positive treatment outcomes to
be seen as the result of a medically-based pharmacological shift, while obscuring the more
meaningful differences resulting from legal as opposed to illegal drug use.
While many participants adopted this rhetorical strategy when describing their treatment
experience (an unsurprising outcome considering the institutional dominance of the disease
model in MMT), others challenged this view by emphasizing the similarities between methadone
and illegal opioids. Some participants even directly rejected the pharmacological distinction
between heroin and methadone, describing them instead as legal versus illegal opioids.
However, participants from the MMT-client group were often reticent to express that view and
admitted to social pressure from family and others to position methadone as a medicine, separate
and distinct from illegal opioids like heroin.
Public health initiatives like recovery are often criticized for their tendency to focus on
individual behavioral change at the expense of structural analyses (Salas, 2015; Walls, Peeters,
Proietto & McNeil, 2011; Merzel & D'afflitti, 2003; Reinarman & Levine, 1997). Reinarman
and Levine argue convincingly that the moral panic surrounding crack cocaine use functioned to
protect the power structure by positioning the structural and institutional issues of urban decay as
resulting from poor moral choices i.e. crack cocaine use (1997). Sociologist Deborah Lupton
argues that public health discourses often mobilize concepts of risk in order to “blame the victim,
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to displace the real reasons for ill-health upon the individual, and to express outrage at behavior
deemed socially unacceptable” (1993: p. 425).
Because people on MMT continue using, and are physically dependent on opioids
(methadone), there has always been a tension between understanding it as a form of drug
treatment, and understanding it as a means of using opioids legally i.e. the common charge that
people on MMT are ‘just swapping one drug for another’ (Doukas, 2011; Kleber, 2009; Fraser &
Valentine, 2008). Unfortunately, most discourses that emphasize the similarities between
methadone and illegal opioids are framed by conservative and anti-drug ideologies, and used to
de-legitimize the treatment. However, the same comparison also challenges criminalization by
rejecting pharmacological explanations for individuals positive treatment experiences on MMT,
and instead positioning methadone’s legality (in MMT) as directly related to its capacity to
produce positive outcomes. Thus, if opioid dependent individuals’ lives dramatically improve by
switching from an illegal opioid to a legal one, then criminalization itself may be a larger part of
the difficulties illegal drug users encounter than acknowledged by medical models of addiction
like recovery.
Limitations
The results of this study should be considered in light of some important limitations. My
own position as someone in MMT is the most notable source of bias. Although (as discussed in
the Methods section) I believe my insider status was primarily an advantage in this study, it
clearly influenced my relationships with participants, and thus the data I collected. I attempted
to control for this both through transparency, and by including multiple participants’ responses
when addressing the study’s major themes. This was done to mitigate concerns of ‘cherrypicking’ only the data that supported my own views. Additionally, since this study is not based
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on a representative sample, the results cannot be generalized to the larger population of
individuals on MMT.
Similarly, since the majority of study participants were located in New York City (NYC),
the results may reflect that community. NYC is a center of drug use, research, and activism, and
participants may therefore be more informed about recovery, harm reduction, and/or the politics
of drug use issues. Similarly, the clinic I attend (and did the majority of my ethnographic
research at) is also the location of Medication Assisted Recovery Services (MARS), one the
primary organizations working to promote recovery-based principles in MMT. Although this
had no direct effect on the study, the clinic environment (posters, announcements, etc.) may
focus on recovery more so than other clinics. For these reasons, I spoke with participants from
outside the state and also visited other clinics (in the NYC area).
Recommendations
The results of this study demonstrate the need for a paradigmatic shift in how MMT is
conceptualized. Specifically, there needs to be discursive space for understanding MMT’s
function as related to dealing with the oppressive effects of criminalization. This does not mean
disallowing or rejecting individuals’ rights to understand their drug use and treatment through
the recovery model. Rather, it means adopting a less positivistic ontology for MMT that rejects
easy binaries and reductive narratives as a means of conceptualizing the ‘treatment’.
Increasing focus should be given to ‘low-threshold clinics’ and other forms of harmreduction-based treatment. Low-threshold clinics are those that “seek to break down barriers to
the treatment of opioid dependence by reducing entry and retention criteria and by accepting
individuals who continue to use drugs without threat of expulsion from the program” (Millson,
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Challacombe, Villeneuve & Strike, 2007: p. 125). Although treatment providers may object to
such clinics on the basis that individuals on MMT who use other substances may be at increased
risk of overdose, studies have found that low-threshold clinics actually reduce the risk of
overdose (Van Ameijden, Langendam & Coutinho, 1999) as well as injection-related HIV risk
(Millson, Challacombe, Villeneuve & Strike, 2007) and improve health related quality of life
among participants (Millson et al. 2006). Moreover, like many critiques of harm reduction
treatment, such claims are based on the falsehood that individuals who wish to continue using
drugs while in MMT will be dissuaded by the possibility of punishment and comply with the
rules. In actuality (and like one participant in this study) many simply abandon treatment and
return to illegal and unregulated – and thus, more risk-involved - opioid use.
However, when such options are unavailable, people who use drugs and like-minded
activists should be open to operating outside of the system. As critical Anthropologist C.B.
Smith points out “Prior to being institutionalized as public health policy…. harm reduction
originated as an illegal activity where activists and politicized front-line workers risked arrest by
distributing clean syringes” (2012, p. 210). Similarly, participants in this study who used MMT
for non-recovery reasons, were most successful when they utilized deception to convince
clinicians that they were, in fact, pursuing recovery. In the oppressive context of criminalization
and the War on Drugs, using deception in order to maintain access to a stable, reliable, and legal
supply of opioids is comparable to underground syringe exchange organizations, illegal safe
consumption spaces, and other forms of traditional harm reduction work.
Most importantly, the culture and institutions involved with MMT must allow for
alternative discourses that position criminalization as oppressive to drug users and acknowledge
the role of treatment (particularly MMT because clients are not required to discontinue opioid
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use) as a refuge. By acknowledging MMT’s use as a protective factor, treatment decisions can
be understood not simply as medical choices but political ones (Smith, 2012). This provides a
more productive framework from which to address criminalization as an oppressive regime. As
Koester et al. rightly conclude: we should consider “drug users’ own models of drug use and
treatment” and that “these addict-led adaptations of methadone maintenance treatment may
encourage us to rethink what we mean by ‘successful’ treatment” (1999: p. 2151).
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